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INTRODUCTION 
 
Heart Failure is a condition when there is acquired/inherited 
abnormality in the function and/or structure of heart leading to signs and 
symptoms that require frequent admissions and lead to decreased life 
span and poor quality of life
1
. Ischemia remains the chief etiology for 
heart failure worldwide. Heart failure is the final common  outcome in all 
pathologies of heart disease. It is associated with a lot of comorbidities 
and lethality across the globe.    
Over the last decade, several biomarkers have emerged in heart 
medicine like uric acid, neurohormones, hsCRP , BNP and many other 
pro inflammatory cytokines which help in the diagnosis as well as 
prognosis of heart failure. 
Recently Red Cell Distribution Width (RDW) was found to be 
elevated in many heart failure cohorts. It is considered as a measure of 
variability in RBC size
2
. It is represented in 2 forms- RDW-CV 
(coefficient of variation) or RDW-SD (standard deviation). It is an easily 
available investigation as most of the hematology instruments measure 
RBC volume and give RDW. An elevated RDW can predict mortality and 
morbidity in heart failure. Various postulates and theories have been put 
2 
 
forth by many researchers for the cause for elevated RDW in the context 
of heart failure.  
Januzzi and coworkers postulated from their research that RDW 
carries more  prognostic information in addition to NT-pro BNP in acute 
heart failure. Few other studies also demonstrated that RDW is markedly 
elevated in severe heart failure independent of anemia and is a marker of 
worst prognosis.  Hence RDW is clearly emerging as a new and 
promising biomarker in heart failure assessment, and candidacy for 
ventricular assist devices, IABPs, CRTs and transplantation. 
Unfortunately there are not many studies comparing RDW with 
severity of  cardiac failure. Here , I have planned to compare the 
parameter RDW in cases of cardiac failure and analyse RDW with 
severity of heart failure based on NYHA class and LV ejection fraction. 
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AIM OF THE STUDY 
 
 To evaluate RDW in heart failure. 
 To correlate RDW with severity of heart failure(NYHA 
functional class and LV ejection fraction). 
 To correlate RDW with morbidity and mortality in follow up 
at the end of one month. 
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REVIEW OF LITERATURE 
HISTORY OF HEART FAILURE: 
MILESTONES 
 1628 William Harvey -  circulation 
 1785 William Withering – cardiac glycosides 
 1920  Diuretics - introduced 
 1954  Imaging of heart- USG 
 1958 Thiazide diuretics   
 1967 Christiaan Barnard  - 1st heart transplant 
 1987 CONSENSUS-I – use of ACE-I in heart failure 
 1995 ESC3- heart failure- guidelines for Rx 
Accounts of heart failure antedates to ancient days. Understanding 
the natural history of heart failure has been phenomenal with significant 
evolutions from the day when Harvey described circulation. Inventions 
ranging from ECG, XRays, ECHO, cardiac catheterisation, newer 
biomarkers and nuclear medicine have succeeded in early diagnosis and 
effective treatment of heart failure patients around the globe. 
Advances in heart failure therapy emerging from newer 
pharmacological agents to the use of surgical techniques, LV 
reconstruction, valvular surgeries, CRTs, ICDs, VADs and heart 
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transplantation have lead to the longevity of patients adding to the global 
burden of heart failure prevalence. 
EPIDEMIOLOGY OF HEART FAILURE 
Each year, new cases of  congestive heart failure develop in about 
550,000 patients. Nearly 1 million people get hospitalised for CHF yearly 
with 6.5 million hospital-days. Each year around 60,000 patients die of 
this condition.  
Approximately one-third to one-half of the deaths in patients with CHF 
are secondary to the progression of cardiac insufficiency and its 
associated conditions. The remainder of the patients with CHF die of 
sudden cardiac death, presumably related to electrical instability and 
ventricular arrhythmias and other cardiovascular conditions as well as 
from noncardiovascular causes. 
Data describing the natural history of CHF are limited due to lack 
of prospective studies
4
. The  prevalence  in  in developed countries is 
2.1%. Its prevalence increases with age, 10%  suffering after they cross 
65 years. It has a low incidence in women but 50% cases constitute 
females due to increased life span. 
The Framingham heart study
5
 showed that men in whom clinical 
symptoms of CHF developed had a 5 year mortality rate of 62%. 
Subsequent studies indicate that heart failure is a progressively 
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deteriorating condition, with 5 year mortality rate of 20–40% .Other 
studies show that patients with advanced CHF have 50% mortality. 
Congestive heart failure is the inability of  the heart to pump blood in par 
with the metabolic demands. It occurs either due to decreased myocardial 
contractility or an increased pressure or volume overload. Its 
haemodynamic consequences are diminished stroke volume (forward 
failure) and pooling back of blood (backward failure) alone or together. 
DEFINITION: 
A pathophysiologic state in which an abnormality of cardiac 
function is responsible for the failure of the heart to pump blood at a rate 
commensurate with the requirements of the metabolizing tissues.
1 
PHYSIOLOGY OF CARDIAC CONTRACTION 
The force of contraction of the myocardium depends on 
 preload 
 afterload 
 inotropic state (contractility)  
 heart rate. 
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Preload: 
According to the Frank-Starling law
6
, increasing the resting length 
of the myocardial fibre can increase the force of isometric contraction. In 
an intact ventricle, the length of the fibre can be increased by increasing 
the end-diastolic wall tension (preload). This in turn is achieved by 
increasing the end-diastolic volume of the ventricle. The beneficial effect 
of increasing fibre length is however limited. Beyond the point of optimal 
stretch, increase in preload causes a decline in the force of isometric 
contraction. 
 
Afterload is defined as the tension or force which develops in the 
ventricular wall after the onset of shortening (systole). 
Contractility or inotropic state of the heart refers to a state of the 
heart muscle, affecting cardiac performance independent of the variations 
resulting from changes in the preload and afterload
7
. With constant 
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loading condition, increased cardiac contractility will augment cardiac 
performance. 
Increased frequency of cardiac contraction increases contractility. 
Its effects in the intact heart are however limited and with rapid heart 
rates, contractility may actually decrease because of limitations of 
coronary blood flow and encroachment on the diastolic filling period. 
TYPES 
Cardiac failure may be classified as follows: 
Acute versus chronic failure 
 Acute heart failure develops after a massive myocardial infarction 
or valve rupture, whereas chronic heart failure is seen in slowly 
progressive valvular heart disease, dilated cardiomyopathy and 
systemic hypertension.  
 In acute failure, sudden reduction in cardiac output leads to 
hypotension with no volume expansion, whereas in chronic heart 
failure there is no reduction of BP but there is oedema over the 
legs. 
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Left-sided versus right-sided failure 
 In left ventricular failure, there is pulmonary congestion resulting 
in dyspnoea and orthopnoea. 
 In right-sided failure, systemic congestion leads to raised jugular 
venous pressure, congestive hepatomegaly, and lower limb 
oedema. 
 In long- standing valvular heart disease (aortic and mitral valve) 
and hypertension, combined features of left and right ventricular 
failure (congestive heart failure) are present. 
High-output failure 
High-output failure is present in 
1. severe anaemia  
2. hyperthyroidism 
3. beriberi 
4. arterio-venous fistula  
5. Paget’s disease 
In most of these conditions, there is an increase in cardiac output to 
meet the oxygen requirement of the body. 
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Forward versus backward failure 
 In backward heart failure the pressure and volume in the atrium 
and venous compartment are elevated, leading to retention of 
sodium and water and resulting in oedema. 
 In forward heart failure, clinical features are explained on the basis 
of inadequate output due to reduced left ventricular systolic 
function, resulting in diminished renal perfusion, which activates 
the renin-angiotensin-aldosterone system with resulting salt and 
water retention and oedema
8
. 
 Both mechanisms operate in varying proportions in a majority of 
patients with heart failure. 
Systolic versus diastolic failure 
Patients with systolic heart failure have predominant systolic 
ventricular dysfunction, mainly due to myocardial dysfunction. The 
common causes are 
 primary heart muscle abnormalities 
1. dilated cardiomyopathy  
2. ischaemic heart disease  
chronic excessive ventricular workload  
11 
 
1. systemic hypertension  
2. valvular heart disease  
3. congenital heart disease . 
Disturbances of lusitropic function, i.e. failure of relaxation of 
ventricle, lead to elevation of ventricular diastolic pressure with normal 
ventricular diastolic volume. The commonest cause of failure of 
relaxation is ischaemic heart disease wherein reduction of myocardial 
perfusion results in diastolic dysfunction
9
. Failure of relaxation can also 
be caused by a stiff or thick ventricle as in restrictive cardiomyopathy 
secondary to infiltrative disorders like amyloidosis or haemochromatosis. 
Lusitropic failure may be local or general. General diastolic dysfunction 
results in cardiac decompensation. Local failure results in failure of 
relaxation or dysdiastole, with non-synchronous coronary flow leading to 
myocardial ischaemia. Dysdiastole occurs early in  
 hypertension, 
 idiopathic hypertrophic subaortic stenosis (IHSS), 
 cardiomyopathy, 
 amyloidosis  
 haemochromatosis  
 constrictive or restrictive disease. 
12 
 
 
Systolic Heart Failure
10 
Diastolic Heart Failure 
Large, dilated heart Small LV cavity, concentric LV 
hypertrophy 
Normal or low blood pressure Systemic hypertension 
Broad age group/ common in 
men 
Elderly women more common 
Low ejection fraction Normal or increased ejection fraction 
S3 gallop S4 gallop 
Systolic/ diastolic impairment by 
echo 
Diastolic impairment by echo 
Treatment well established Treatment not well established 
Poor prognosis Prognosis is poor after hospitalization 
is required for heart failure 
Role of myocardial ischemia 
important in selected cases 
Myocardial ischemia common 
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Heart failure is now classified as 
 heart failure with normal ejection fraction6 40%-50% 
 heart failure with reduced ejection fraction <40% 
SPECTRUM OF HEART FAILURE: 
The syndrome of cardiac failure encompasses the following 
spectrum. 
 
PATHOGENESIS OF HEART FAILURE: 
Following any insult / injury
6
, the myocardium responds by 
undergoing remodelling. Initially it preserves the cardiac output and 
eventually it proves to be maladaptive and results in clinical features of 
Heart 
Failure 
Symptoms 
Systolic 
dysfunction 
Exercise 
intolerance 
Ventricular 
arrhythmias 
Volume 
retention 
Renal 
dysfunction 
Neurohormonal 
activation 
Diastolic 
dysfunction 
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cardiacfailure.
 
Increased peripheral vascular resistance compensates for the 
decreased cardiac output. But overcompensation can lead to an increased 
afterload which affects the ventricular function adversely, leading to 
worsening of heart failure. Thus a vicious cycle sets in 
 
INDEX EVENT 
•Acute MI 
•Genetic mutations 
•Acute inflammation 
•Hypertension 
•Valvular heart disease 
REMODELING AND 
DISEASE PROGRESSION 
•Myocyte hypertrophy 
•Fibrosis 
•Collagen dissolution 
•Apoptosis 
•Necrosis 
•Neurohormonal 
response 
•Cytokines 
•Wallstress 
•Chamber dysfunction 
 
CLINICAL FEATURES 
•Sodium retention 
•Water retention 
•Edema 
•Dyspnea 
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Possible Mechanisms of Myocardial Failure  
 Loss of myocytes /Hypertrophy of remaining myocytes  
 Inadequate O2 /energy supply 
 Inadequate  substrate utilization/energy storage   
 Inadequate mitochondrial function 10 
 Ventricular remodeling  
 Contractile protein abnormality/ defective synthesis  
 Abnormal myofibrillar or myosin ATPase                    
 Activation of contractile elements --Membrane Na+,K+-
ATPase defects 
 Abnormal sarcoplasmic reticulum function --Abnormal Ca2+ 
release/uptake 
 Abnormal myocardial receptor function  
 Downregulation of  adrenoreceptors 
 Decreased Gs protein /Increased G1 protein  
 Increased myocardial fibroblast growth and collagen synthesis 
 Abnormal myocardial norepinephrine function or kinetics  
 Abnormal baroreceptor function  
 Aging changes/ presbycardia  
 Sustained tachycardia  
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NEUROHORMONAL CHANGES IN HEART FAILURE
11 
1. Increased sympathetic nervous system activity (increased 
norepinephrine/ epinephrine)  
2. Increased endothelin  
3. Increased arginine vasopressin  
4. Increased renin and angiotensin II  
5. Increased aldosterone  
6. Increased neuropeptide Y  
7. Increased natriuretic peptides –ANP/BNP 
8. Increased Insulin  
9. Increased Cortisol  
10. Increased GH 
11. Decreased IGF 
12. Increased TNF 
13. Increased IL6 
14. Increased VIP 
15. Increased Adrenomedullin  
16. Increased Urodilantin  
17. Increased Urotensin-II  
18. Increased Cardiotrophin-I  
19. Increased dopamine  
20. Increased PGI2/ PGE2 
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21. Increased vasodilator peptides (bradykinin)  
 
 
SEQUENCE OF EVENTS IN HEMODYNAMIC ADAPTATIONS 
IN CARDIAC FAILURE
10 
Increase in 
1. LVEDV/LVEDP 
2. Atrial volume/ pressure 
3. Atrial /ventricular contractility (Starling law) 
4. Volume and pressure in venous system 
5. Capillary pressure / secondary transudation of fluid 
6. Interstitial / extracellular fluid volume  
7. Lymphatic flow from interstitial spaces 
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Factors Associated with Left Ventricular Diastolic Dysfunction. 
 Hypertension  
 CAD 
 IHD 
 Myocardial Scarring  
 LVH 
 DCM   
 Myocardial fibrosis   
 Constrictive pericarditis  
 Infiltrative diseases   
 
Stages of diastolic dysfunction
8 
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With myocardial failure, ventricular dilatation can occur, 
maintaining stroke volume (the Starling effect). This dilatation can lead 
to failure of the mitral valves to close completely, resulting in mitral 
regurgitation. This then creates a secondary functional volume load for 
the already compromised LV. The schema of the sequence of events in 
heart failure is daunting. Distinguishing primary etiologic forces from 
secondary epiphenomena is difficult. Identification of the precise 
mechanisms whereby heart failure evolves and quantifying the 
contributions of individual components such as a primary decrease in 
capacity of myocytes to shorten adequately (eg, decreased contractility) 
or loss of myocytes (eg, apoptosis or myocardial necrosis) has remained 
elusive. Indeed, loss of myocytes with compensatory dilatation of the 
ventricle can lead to further loss of myocytes.  
20 
 
 
What triggers the early activation of the sympathetic nervous 
system and withdrawal of vagal tone and how spontaneous resolution of 
heart failure occurs remains unclear. Nevertheless, enough information 
has accrued to construct a reasonably coherent working hypothesis. 
Molecular Adaptations and Maladaptations: Altered Cellular 
Proteins 
The growth of genetics and molecular cardiology has provided 
important insights into the pathophysiology of heart failure . However, 
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because the cause and progression of heart failure is complex, both 
environment and genetics play important roles. Thus, there is no single 
cause or unifying mechanism of heart failure, and current therapeutic 
strategies target multiple pathophysiologic processes. 
Alterations are found in the failing heart in numerous contractile proteins, 
especially in heredity-based idiopathic dilated cardiomyopathies. In the 
latter situation, these alterations can interact with abnormal loading 
conditions to cause heart failure. Such alterations have been found in the 
proteins of the cytoskeleton, myosin, troponin T, and actin and are likely 
to contribute to diminished myocardial performance. In animal models, 
various overloads can result in heart failure, whether from systolic loads 
(hypertension), loss of myocardium (infarction), inflammation, and so 
forth. Furthermore, in human failing hearts, the etiology can be modified 
from that in animal models. In the failing human heart, many changes in 
gene expression at the mRNA or protein level have been found in failing 
hearts harvested at the time of cardiac transplantation. However, these are 
often hearts with end-stage myocardial disease in which many factors (eg, 
receiving multiple inotropic drugs) can obscure the initial pathogenesis. 
Sarcomeric Proteins 
More than half of the volume of cardiac myocytes contains 
contractile proteins. Myosin comprises the thick filament that hydrolyzes 
22 
 
adenosine triphosphate (ATP), interacts with the thin actin filaments to 
produce force and shortening. Two myosin heavy-chain (MHC) isoforms 
are present in mammalian heart, α–MHC and β–MHC. The α–MHC is 
cardiac specific and is more enzymatically active. The less active β–MHC 
is present in the heart and in slow-twitch skeletal muscle. The distribution 
of α–MHC and β–MHC is developmentally and hormonally regulated. 
Mechanical stress, such as pressure overload, induces an α–MHC to β–
MHC transition in the ventricles of experimental animals, thus imparting 
a slower but more economical type of work for the overloaded heart. 
Either way, myosin remains a principal structural and contractile unit of 
muscle fiber. 
23 
 
 ALTERATIONS IN VENTRICULAR FUNCTION   SYSTOLIC 
HEART  FAILURE                                                                                
 
 
There is a general agreement that myofibrillar function is depressed 
in the failing human heart, but its causal role remains controversial. 
Although such adaptive changes could be viewed to have an economical 
survival advantage in the face of increased load, slower contraction and 
relaxation could also contribute to diastolic dysfunction. In addition, 
isoform changes involving both the heavy and the light chains, as been 
suggested, can play a role in heart failure. In addition to myosin heavy- 
↑mechanical        
loading 
↑neurohormone 
normal 
failure 
Sarcomere dysfunction Signal transduction 
angiogenesis 
Myocyte 
death 
Electrical 
remodelin
g 
fibrosis 
Altered metabolism/ 
energetics 
Altered 
calcium 
homeostasis 
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and light-chain isoform switches, other well-understood pathologic events 
also contribute to altered cardiac function in various forms of heart 
failure. Point mutations of virtually all of the sarcomeric proteins cause 
hypertrophic cardiomyopathy . Similarly, mutations in the cytoskeletal 
proteins that provide the molecular scaffold for the sarcomere have been 
found in both dilated and hypertrophic cardiomyopathies. 
Echocardiographic studies have demonstrated that 20% of first-degree 
relatives of patients with idiopathic dilated cardiomyopathy have enlarged 
LV cavities.  
Cell Membrane Ion Channels and Intracellular Calcium Kinetic 
Proteins 
Plasma membrane ion channels initiate excitation–contraction by 
generating and then propagating the action potentials that depolarize the 
myocardium. These ion channels are complex and contain several 
subunits that surround the ion-selective pore. The intracellular calcium 
(Ca
2+
) release channels are found in the sarcoplasmic reticulum (SR) and 
are quite different from those of the plasma membrane. The SR Ca
2+
 
release channels are referred to as ryanodine receptors (RyRs) and 
interact with the ligand inositol triphosphate (IP3). The Ca
2+
 pump 
ATPases are found in both the plasma membrane and SR. Both calcium 
pumps are activated by cytosolic Ca
2+
. The heart's voltage-gated ion 
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channels (especially inward sodium channels) are altered in the failing 
heart,
7
 as are outwardly rectifying potassium channels
12
. A common 
feature of animal models of heart failure and clinical heart failure in 
humans is prolongation of the action potential. Both decreased sodium 
influx and potassium efflux are contributory and are mediated by reduced 
activity of the sarcolemmal sodium and potassium channels, respectively. 
This aberrant channel behavior contributes to the arrhythmias, which are 
the second most common cause of death of patients with heart failure. 
Multiple additional mechanisms are also contributory, including excess 
sympathetic stimulation and extracellular matrix–induced scar formation. 
Excitation–Contraction Coupling Proteins 
The basic mechanism of cardiac excitation–contraction coupling 
involves calcium (Ca
2+
) entry from the extracellular fluid by means of the 
voltage-dependent L-type calcium channel to produce a trigger in 
increasing [Ca
2+
]i and opening of the intracellular SR Ca
2+
 release 
channel or RyR. Defects in sarcolemma Ca
2+
 uptake (sarcolemmal 
transport via Na
+
,K
+
-ATPase) and release by the SR are present in heart 
failure, especially at later stages,
13
 but uptake of calcium by the SR can 
remain intact. These alterations in calcium transport can be secondary to 
quantitative alterations of gene expression of SR calcium transport 
proteins like SERCA and phospholamban, a reversible inhibitor of 
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cardiac SR Ca
2+
-ATPase activity. Other calcium-cycling proteins such as 
Na
+
-Ca
2+
 exchanger proteins
14
 can also be altered in heart failure. 
Phosphokinase A hyperphosphorylation of RyR has recently been shown 
to alter calcium signaling from the SR by depleting calcium stores and 
reducing calcium transients that can impair contractility in the failing 
myocardium.
15
Several of these alterations can occur concurrently and can 
vary from model to model and may not always be relative to failing 
human hearts. Nevertheless, it is likely that heart failure is characterized 
by reduced myofilament activation and decreased calcium available for 
activation as well as heightened cytosolic calcium levels in diastole. 
Some studies have shown increased myofibrillar calcium sensitivity
16
 and 
altered calcium kinetics. These abnormalities of calcium metabolism can 
be of primary importance in some types of heart failure, and they can be 
secondary or epiphenomena in other types. Most abnormalities of 
myocardial contractile activation have been demonstrated only in the late 
stages of heart failure and therefore can be the result of maladaptive 
hypertrophy rather than a primary cause of ventricular dysfunction.  
Metabolic  Maladaptations 
Energy Production and Use 
High energy phosphate levels are reduced in both animal models of 
heart failure
17
 and failing human hearts.
18
 Levels of phosphocreatine (PC) 
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are more depressed than ATP. Reduced PC levels impair the shuttle that 
normally transfers energy from the mitochondria to the cytosol. The 
abnormal pattern of energy production in the failing heart resembles that 
of the fetal heart. This is also true of abnormalities in excitation–
contraction coupling, myocyte contraction, and myocyte relaxation. In 
essence, the failing (and fetal) heart is less reliant on the more efficient 
pathways of mitochondrial ATP production. Less high-energy phosphates 
are available to meet the increased work demands of the failing heart. 
Even a small reduction in the phosphorylation potential impairs ATP-
dependent reactions because the heart has only a small phosphorylation 
reserve capacity. Moreover, decreased PC levels reflect more PC use 
rather than a lack of adequate PC. 
Oxygen deprivation, which is most often caused by coronary artery 
disease, results in impaired relaxation and weakened contraction, as can 
be seen in transient angina pectoris. This is readily reversible. With 
prolonged ischemia, decreased contraction (dyskinesis) can persist for 
hours beyond return of blood flow (stunning). If coronary blood flow is 
chronically reduced, the myocardium can fail to contract normally 
(hibernation), even if necrosis does not ensue . With a more serious loss 
of flow, infarction can occur. All of these stages can produce substantial 
dyskinesia for which the remaining myocardium must sustain this load. 
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The result is hypertrophy of the nonischemic portion of the ventricle; if 
this is inadequate, an increase in ventricular volume occurs using the 
Frank-Starling mechanism to sustain SV. Whether there is a true 
limitation of energy supply or its use in the failing myocardium remains 
controversial. 
In cardiac failure, the total oxygen requirement of the heart can be 
increased significantly because of the increased total mass, the increase in 
myocardial systolic wall tension because of the Laplace relationship, and 
perhaps some wasted contractile energy. This increase can result in the 
extraction of a greater amount of oxygen from each unit of coronary 
blood flow and a widening of the coronary arteriovenous oxygen 
difference. These patients are able to increase coronary blood flow during 
exercise; however, some patients with a dilated ventricle that increases in 
diameter during exercise can have a further widening of the coronary 
arteriovenous oxygen difference during exercise and a decrease in 
coronary blood flow reserve . Tachycardia, such as can occur with atrial 
fibrillation, can reduce diastolic time for coronary perfusion, producing 
ischemic ventricular failure.  
Substrate Use and Energy Storage 
Although the myocardial uptake of fatty acids and glucose per 100 
g of myocardium is normal in heart failure, there is conflicting evidence 
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on whether or not there is a primary decrease in energy liberation by 
mitochondrial oxidative phosphorylation. The reductions in stores of 
myocardial high-energy phosphate, creatine phosphate, or ATP generally 
found in heart failure are thought to be secondary. This can be a 
consequence of the failure rather than the primary cause of the failure. 
There can also be reduced levels of creatine kinase and changes in the 
isoenzymes of creatine kinase in heart failure. 
The major consequences of the state of energy starvation that is 
observed in failing hearts is not due to absolute reduction in ATP. It is the 
altered allosteric or regulatory effects of ATP which exert both inotropic 
and lusitropic effects . 
Mitochondrial Mass and Function 
Except when coronary flow is limited, such as with large vessel 
obstructive disease  or purported microvascular obstructive or vasospastic 
disease, a primary role of energy limitation such as mitochondrial mass 
and function in the evolution of heart failure has yet to be demonstrated. 
It is possible that it plays a role during periods of higher metabolic 
demand, such as tachycardia, as noted previously.
19
 Furthermore, 
mitochondrial dysfunction can produce increased reactive oxygen species 
(ROS) that can produce additional damage and death of myocytes. 
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Hibernation and Stunned Myocardium 
Systolic ventricular dysfunction as a result of focal loss of 
contraction can be dynamic and transient as can occur with acute 
ischemia. With restoration of metabolic requirements of an ischemic 
segment of myocardium, either from restoring adequate coronary flow or 
reducing oxygen requirements, myocardial contraction can be restored. 
Sometimes restoration is delayed, so-called stunning. Chronically 
reduced coronary flow can be inadequate to preserve contraction but 
adequate for myocardial survival. Such persistent depressed myocardium 
has been termed hibernation and with reperfusion can recover 
contractility over a period of time . 
Physiologic  Maladaptations 
Autonomic Nervous System Dysfunction 
An increase in systemic vascular resistance (SVR) is generally 
observed in well-established heart failure. It is likely caused by a 
combination of locally active heightened vasoconstrictors 
(norepinephrine [NE], angiotensin II, endothelin, vasopressin, 
neuropeptide Y) and by structural changes in blood vessels from fluid 
retention and reduced endothelial-dependent vasodilatation. These later 
changes are closely associated with limitations of exercise in heart 
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failure. Early in heart failure, there may be a decrease in cardiac output, 
arterial pressure, and baroreceptor activity, leading to an adaptive 
increase in excessive neuroendocrine drive. 
 
The first adaptive change is activation of sympathetic nervous 
system, followed by the renin–angiotensin–aldosterone system (RAAS). 
ADH is released that leads to Sodium and water retention which 
maintains the cardiac output initially.However, as heart failure 
progresses, there is impaired cardiosensory activity that fails to reduce 
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neuroendocrine drive. For unclear reasons, cardiac afferent activity to the 
central nervous system is reduced, leading to unhindered, efferent 
excitatory responses from the brain to the periphery. Reflex 
vasoconstrictor responses to unload the heart are paradoxically blunted.
20
 
There are abnormal vascular responses to postural change. Some of these 
changes lead to alterations in regional blood flow that accompany heart 
failure. Parasympathetic (vagal) tone is decreased, and heart rate 
variability is markedly reduced, a hallmark of congestive failure. 
Furthermore, decreased heart rate variability can provide independent 
prognostic value in the identification of patients at risk for premature 
death.
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Although the genesis of these abnormal reflex control mechanisms 
is poorly understood, the changes can be more functional than structural. 
Heart transplantation reverses cardiopulmonary baroreflex control 
mechanisms to some extent, but this is inconsistent. The role played by 
abnormal reflex control mechanisms in the progression of heart failure, 
similar to other neuroendocrine alterations, has been difficult to quantify. 
Nevertheless, it is now increasingly clear that the sympathetic nervous 
system and the RAAS greatly influence the progression and natural 
history of heart failure with very important therapeutic implications. 
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Myocardial Receptor Dysfunction 
The failing heart commonly demonstrates a decreased response to 
inotropic stimuli. Although no single mechanism accounts for this, the 
reduction in myocardial β–adrenergic receptors and the subsequent 
second messenger cyclic adenosine monophosphate (cAMP) can play an 
important role.
22
 β–Adrenergic stimulation contributes importantly to the 
cardiac response to exercise, and β–adrenergic desensitization and 
uncoupling can be at least partially responsible for the reduced 
chronotropic and inotropic response to peak exercise commonly found in 
patients with heart failure. The β–adrenergic receptor abnormalities in 
heart failure appear to be caused by desensitization and uncoupling of the 
β1 receptor produced by local rather than systemic alterations in 
catecholamines. In severe heart failure, the NE stores in sympathetic 
nerve endings are depleted. In a sense, the failing myocardium becomes 
functionally denervated. cAMP responses are reduced by approximately 
30% to 35%, leading to further contractile dysfunction. Despite 
downregulation of the β1 receptor, a relatively high proportion of β2 
receptors remains to mediate chronotropic and inotropic responses.
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However, there is some uncoupling of the β2 receptor from its G protein 
and a modest upregulation of the Gi subunit, further contributing to a 
depressed response to chronotropic and inotropic stimuli.
24
 There is also a 
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profound decrease in cardiac β–adrenergic responsiveness with aging,25 
which has clinical implications because heart failure is heavily 
concentrated in the elderly population. 
The desensitization and uncoupling of β –adrenergic receptors that 
occurs early with mild to moderate ventricular dysfunction is related to 
the degree of heart failure and is associated with a very reduced response 
to  β–adrenergic stimulation with drugs such as dobutamine. Long-term 
stimulation of β–adrenergic receptors can enhance myocardial β–
adrenergic receptor kinase activity,
26
 leading to further desensitization 
and uncoupling of the β –adrenergic receptor. 
Of great therapeutic interest, β–adrenergic blockade with 
metoprolol, a relatively cardioselective β1-blocker, upregulates the β1 
receptor, but carvedilol, a nonselective β1- and β2-blocker with additional 
β1 blocking activity, does not increase β1 receptor density.
27
 Both drugs 
improve LV function substantially in approximately two-thirds of 
patients. The ventricular improvement seen with chronic β-blocker use 
may not be caused by upregulation of β–adrenergic receptors, and the 
beneficial effects of β–adrenergic receptor blockade in heart failure 
remains unexplained. Moreover, high plasma NE levels do not predict 
benefit from carvedilol,
28
 suggesting that there is not a simple relationship 
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between activation of the sympathetic nervous system and response to β –
adrenergic blocking drugs in patients with heart failure. 
Force–Frequency Response to Heart Failure 
The failing human myocardium is characterized by an abnormal 
force–frequency response that parallels the severity of heart failure. 
Normally, an increase in the frequency of stimulation is accompanied by 
an increased rate of force development, a decreased duration of 
contraction, and an enhanced rate of relaxation (Bowditch effect). This 
tends to preserve or increase contractile force while preserving diastolic 
time. The latter effect is important in the tachycardic intact heart in 
preserving time in diastole to prevent ventricular filling and coronary 
blood flow. In isolated failing heart muscle, an increase in heart rate has 
been accompanied by a decrease in myocardial performance. Some 
impairment of systolic function in response to increased heart rate can 
also be related to impaired LV filling, although a negative inotropic effect 
as shown in isolated muscle has been related to alterations in intracellular 
Ca
2+
 handling. A reduced force of contraction and lack of shortening of 
contractile activity can contribute importantly to impairment of cardiac 
function during exercise. 
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Hemodynamic maladaptations: The Hemodynamic Hypothesis 
The term heart failure implies structural heart disease, and the 
central problem of heart failure remains impaired cardiac performance, 
although many of the secondary adaptive responses become maladaptive 
and contribute substantially to the progression of heart failure. In cardiac 
failure, the ventricular end-diastolic pressure (EDP) and the cardiac 
output can be normal at rest, but the former can become elevated to 
abnormal levels during stress such as exercise with increased cardiac 
output or an increase in afterload as the blood pressure increases. The 
ability to increase the cardiac output in response to the increase in oxygen 
consumption is also reduced. In severe systolic dysfunction, the EDP can 
be elevated even at rest. As the diastolic volume is increased, so is the 
end-systolic volume. This results in reduced elastic recoil of the ventricle 
during relaxation and is reflected in loss of rapid early diastolic 
ventricular filling (as revealed by a reduced E wave of the 
echocardiogram). This helps further increase the mean diastolic pressure. 
The elevated LV diastolic pressure increases pulmonary venous and 
capillary pressures and contributes to increased dyspnea as a result of 
changes in pulmonary compliance because of pulmonary congestion and 
edema. Before one reaches this stage of clinical heart failure, the body 
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has used many compensatory mechanisms, but compensatory 
mechanisms eventually have failed. 
 
Summarising the pathophysiology of heart failure, five ideas are 
being considered: 
1. The damaged heart can itself release cytokines, which activate 
systems elsewhere in the body. 
2. The continued stimulation of the sympathetic system, possibly by 
neural pathways from receptors in skeletal muscle, can account in 
the long-term for cytokine activation. 
3. Tissue hypoxia may contribute. 
4. Imbalance of the autonomic nervous system modifies the function 
of the immune system. 
5. Bacteria or endotoxins can gain access to the circulation and 
stimulate monocytes to generate cytokines. 
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Causes precipitating heart failure 
o Cardiac arrhythmias 
o Pulmonary embolism 
o Infections, particularly lung infections 
o Rheumatic or viral myocarditis 
o Infective endocarditis 
o Anaemia2 
o Conditions with increased metabolic demand (pregnancy, 
thyrotoxicosis) 
o Acute coronary insufficiency or myocardial infarction 
o Accelerated hypertension 
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o Severe physical work or emotional excess increase cardiac 
workload  
o Discontinuation of therapy (patient noncompliance or 
physician initiated)   
o Other factors  
 Initiation of medications that worsen heart failure10 
(calcium antagonists, β-blockers, nonsteroidal anti-
inflammatory drugs, antiarrhythmic agents)   
 Iatrogenic volume overload (transfusion, fluid 
administration)   
 Dietary indiscretion   
 Alcohol consumption   
 Exposure to high altitude 
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Stages of heart failure 
Stage A: HIGH RISK - ( SHT, DM, CAD, family h/o cardiomyopathy) 
Stage B: ASYMPTOMATIC HF- heart disease without symptoms 
(previous MI, LVH, asymptomatic valvular disease) 
Stage C: SYMPTOMATIC HF  (NYHA classes II-IV) 
Stage D: REFRACTORY ENDSTAGE HF- Patients with marked 
symptoms at rest despite maximum therapy who require repeated or 
prolonged hospitalizations/special cardiac support 
 
 
 New York Heart Association classification
29 
Class I: Symptoms only at levels of activity that would produce 
symptoms in normal individuals; ordinary physical activity does not 
cause undue dyspnea or fatigue 
Class II: Symptoms on ordinary exertion, resulting in mild limitation of 
physical activity 
Class III: Symptoms on less than ordinary exertion, resulting in marked 
limitation of physical activity 
Class IV: Symptoms at rest or minimal exertion, resulting in inability to 
carry on any physical activity without discomfort 
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DIAGNOSIS 
There is no gold standard diagnostic criteria for heart failure.  
Named criteria include 
1. Boston criteria30 
2. Duke criteria31 
3. Killip32 class ( in the context of ACS) 
4. Framingham criteria5  
Framingham criteria (100% sensitive & 78% specific) 
Diagnosis of cardiac failure needs 
 2  major criteria  
 1 major +2 minor criteria 
Major criteria
5: 
 
 Cardiomegaly   
 PND 
 S3 gallop  
 Basal rales 
 Jugular vein distension  
 Acute pulmonary edema   
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 Elevated Central venous pressure 
  Positive abdominojugular reflux 
 Treatment induced weight loss  more than 4.5 kg  
Minor criteria
5
:  
  Heart rate more than 120/min  
  Nocturnal cough  
 Shortness of breath 
  Pleural effusion  
  ↓ vital capacity ( 1/3 from maximum)  
  Hepatomegaly  
 Pedal edema  
INVESTIGATIONS 
XRAY CHEST 
1. Pulmonary venous hypertension - dilatation and engorgement of 
the upper lobe pulmonary veins.  
2. Generalised haze (due to interstitial oedema) 
3. Kerley’s B lines (due to prominent interlobular lymphatics) at the 
lung base 
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4. pleural effusion and interlobar thickening due to fluid collection.  
5. dilated pulmonary artery  
6. alveolar pulmonary oedema - butterfly appearance. 
7. dilated superior vena cava and azygos veins systemic venous 
congestion. 
8. cardiomegaly 
 
Electrocardiography  
1. LVH 
2. LAE/RAE 
3. BUNDLE BRANCH BLOCK 
4. PATHOLOGICAL Q WAVES 
5. AF 
6. VENTRICULAR ARRHYTHMIA 
Echocardiography/Doppler studies help in finding details about 
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 valvular lesions, 
  hypertrophic subaortic stenosis,  
 ruptured chordae of the mitral valve, 
  valvular vegetations,  
 left atrial myxoma, 
  cardiac chamber dilatation   
 pericardial effusion.  
 ventricular ejection fraction33 
  ventricular volumes. 
  Regional wall motion abnormality 
Radionuclide studies:  
non-invasive and accurate measurement of wall motion 
abnormalities, ventricular volume and ejection fraction. 
Cardiac catheterisation:  
In CCF, there is increased end-diastolic ventricular pressure, 
reduced cardiac output with inadequate response to exercise, and reduced 
ventricular ejection fraction. Cardiac catheterisation is useful to 
determine the cause of heart failure and for grading the severity of the 
underlying heart disease 
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Laboratory investigations: 
 A low serum sodium concentration indicates a stimulated renin-
angiotensin system as well as increased vasopressin levels and is 
observed in patients requiring large doses of loop diuretics. 
  A low serum potassium level and contraction alkalosis may also 
be observed in patients receiving diuretic therapy. 
  An elevated blood urea nitrogen or serum creatinine level suggests 
either organic or functional renal impairment, caused by 
vasoconstriction, and decreased cardiac output.  
 Liver-function abnormalities may suggest hepatic congestion.  
 Thyroid-stimulating hormone should be measured at the initial 
evaluation, because both hypothyroidism and hyperthyroidism can 
be a primary contributor to the cause of heart failure.  
 Measurement of creatine phosphokinase and isoenzymes, as well 
as troponin I or troponin T may indicate the presence of active 
inflammation or ischemic injury to the heart. 
 Screening for human immunodeficiency virus is recommended for 
patients with high-risk exposures or a history of sexually 
transmitted diseases, with manifestations of infection with the virus 
such as lymphopenia, anemia, cachexia, or history of opportunistic 
infections. 
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GENERAL THERAPEUTIC APPROACH TO CHRONIC HEART 
FAILURE
 
Determine the etiology 
Look for precipitating factors and correct them  
Nonpharmacologic treatment 
Sodium restriction (< 2 g/d) 
Aerobic exercise 
Weight loss in obese patients 
Treat hypertension and other comorbidities vigorously 
Pharmacologic treatment 
Angiotensin-converting enzyme inhibitors (ACEIs) 
Angiotensin receptor blockers (ARBs) 
Aldosterone antagonists 
beta-Blockers 
Vasodilators (long-acting nitrates and hydralazine) 
Diuretics 
Digoxin 
Device therapies 
Cardiac resynchronization therapy (CRT) 
Implantable cardioverter defibrillators (ICDs) 
Left ventricular assist devices (LVADs) 
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RISK STRATIFICATION IN HEART FAILURE 
The following parameters
50
 are strongly associated with increased 
mortality in chronic heart failure and are recommended in risk 
stratification.  
 Advanced age  
 Low serum sodium  
 VO2 max (mL/kg per min <10–14)  
 Low LV ejection fraction33 
 Resuscitated sudden arrest  
 NYHA functional Class III–IV  
 Persistent low BP  
 High serum BNP34,35 
 Increased left ventricular volumes  
 High serum creatinine  
 High serum bilirubin 
 homocysteine 43 
  low body-mass index, 
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  broad QRS36 
 , T-wave alternans37,  
 low heart rate variability,  
 low 6 min walking ability,  
 high left ventricular filling pressure,  
 restrictive mitral filling pattern38,  
 impaired right ventricular function,  
 high serum uric acid39,48, 
 high plasma interleukin –640, 
 high plasma oxidised LDL41, 
 low cardiac index, high resting heart rate and high serum 
norepinephrine
42
 portend a bad prognosis in these patients.  
 The inherent limitations associated with these factors necessitate 
the use of more than one factor in prognostication of chronic HF. 
Predictability and cost efficacy concerns have inculcated further 
studies in this area. 
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NEED FOR A PROGNOSTIC BIOMARKER
49
- WHERE ARE WE? 
Latest biomarkers include 
 ST2 
 Galectin-3 
 Neuregulin-1 
 Copeptin  
 pro-adrenomedullin  
 ANP/BNP 
  sTWEAK  
All these investigations are costly and cannot be done 
everywhere.The quest for a cheap and easily available test has been 
successful and the results are promising, though with limited research 
globally. Recently Red Cell Distribution Width (RDW) was found to be 
elevated in many heart failure cohorts
44
.It is considered as a measure of 
variability in RBC size. It is represented in 2 forms- RDW-CV 
(coefficient of variation) or RDW-SD (standard deviation). It is an easily 
available investigation as most of the hematology instruments measure 
RBC volume and give RDW. An elevated RDW can predict mortality and 
morbidity in heart failure. Various postulates and theories have been put 
forth by many researchers for the cause for elevated RDW in the context 
of heart failure.  
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RED CELL DISTRIBUTION WIDTH- WHAT IS IT? 
In addition to the MCV, MCH, and MCHC, automated counters 
provide an index of the distribution of red blood cell volumes, termed the 
red blood cell distribution width (RDW). Counters use two methods to 
calculate this value. The first is referred to as the RDW-CV. The RDW-
CV is the ratio of the width of the red blood cell distribution curve at 1 
SD divided by the MCV (normal RDW-CV = 13 Â± 1%). Since it is a 
ratio, changes in either the width of the curve or the MCV will influence 
the result. Microcytosis will tend to magnify any change in the RDW-CV 
simply by reducing the denominator of the ratio. Conversely, 
macrocytosis will tend to counterbalance the change in the width of the 
curve and thereby minimize the change in the RDW-CV
2
. A second 
method of measuring the RDW, the RDW-SD, is independent of the 
MCV. The RDW-SD is a direct measurement of the red blood cell 
distribution width taken at the 20% frequency level (normal RDW-SD = 
42 Â± 4fL). 
Both measurements of the RDW are essentially mathematical 
representations of anisocytosis (ie, variations in red blood cell size). 
Increases in the RDW suggest the presence of a mixed population of 
cells. Double populations, whether microcytic cells mixed with normal 
cells or macrocytic cells mixed with normal cells, will widen the curve 
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and increase the RDW. The RDW-SD is more sensitive to the appearance 
of minor populations of macrocytes or microcytes since it is measured 
lower on the red cell volume distribution curve . At the same time, it is 
overly sensitive to the impact of increased numbers of reticulocytes, 
which, because of their larger MCV, will broaden the base of the 
distribution curve. The RDW-CV is less sensitive to the appearance of 
small populations of microcytes, true macrocytes, or reticulocytes, but 
better reflects the overall change in size distribution seen with well 
established macrocytic or microcytic anemias . 
CONDITIONS WITH ELEVATED RDW LOW MCV 
 Iron deficiency anemia 
 Thalassemia 
CONDITIONS WITH ELEVATED RDW WITH LOW OR 
INCREASED MCV 
 B12 deficiency 
 Folate deficiency 
 Recent transfusion 
CONDITIONS WITH ELEVATED RDW/ ELEVATED MCV 
 Liver disease 
 Hemolytic anemia 
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MECHANISMS FOR ELEVATED RDW IN HEART FAILURE 
 Inflammation mediated 
 
 Proinflammatory cytokines 
1. Suppress erythropoietin gene expression45 
2. Inhibit proliferation of erythroid progenitor cells 
3. Downregulate erythropoietin receptor expression 
4. Decrease RBC life span 
 ANEMIA as cause for elevated RDW 
1. Anemia of chronic disease46 
2. Disordered iron metabolism 
3. Renal impairment 
4. Hemodilution 
 Bone marrow resistance to erythropoietin 
Elevations of IL1beta, 
TNFalpha, IL6 
Erythropoietin induced 
RBC maturation 
Elevated RDW 
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 Oxidative stress induced anisocytosis and decreased RBC 
survival
47
 
Januzzi and coworkers postulated from their research that RDW 
carries more  prognostic information in addition to NT-pro BNP
47
 in 
acute heart failure. Few other studies also demonstrated that RDW is 
markedly elevated in severe heart failure independent of anemia and is a 
marker of worst prognosis.  Hence RDW is clearly emerging as a new 
and promising biomarker in heart failure assessment, and candidacy for 
ventricular assist devices, IABPs, CRTs and transplantation. 
Unfortunately there are not many studies comparing RDW with 
severity of  cardiac failure. Here , I have planned to compare the 
parameter RDW in cases of cardiac failure and analyse RDW with 
severity of heart failure based on NYHA functional class as well as LV 
ejection fraction. 
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MATERIALS AND METHODS 
Study centre 
Institute of Internal Medicine, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai 
Study design 
Case control study 
Duration of the study 
6 months 
Sample  
100 subjects with clinical evidence of heart failure were selected 
after applying exclusion criteria. Both inpatients as well as outpatients 
were selected.100 controls were selected with matching gender and age. 
Informed consent was obtained from all patients. 
Inclusion criteria 
 Patients aged between 16 and 80 of both gender 
 Known patients of heart failure 
 Newly detected patients of heart failure 
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 Heart failure patients both with preserved as well as reduced 
EF 
Exclusion criteria 
 Liver disease 
 Renal disease 
 Anemia with haemoglobin < 12 g/dl 
 Blood transfusion within past 3 months 
 Haematological malignancy 
Methodology 
All cases were subjected to a detailed history taking and clinical 
examination based on a simple questionnaire which included complaints 
like dyspnoea, chest pain, orthopnoea, PND, nocturnal cough, syncope, 
palpitations,etc.  All risk factors like smoking, alcoholism, hypertension, 
diabetes, dyslipidemia, coronary artery disease, heart failure and 
medications were taken into account. NYHA functional class was applied 
and patients were classified into 4 classes of heart failure. Clinical 
features like rales, jugular venous distension,edema,S3 gallop were noted. 
Body mass index was also calculated for all patients. Fasting and post 
prandial blood glucose, fasting lipid profile, blood urea, serum creatinine, 
serum electrolytes, bilirubin, liver enzymes and albumin were measured 
in all these patients. ECG, XRay chest and 2-D echo were taken for all 
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these patients. USG abdomen was also done. Based on history, 
examination and investigation results, complete blood count with Red 
Cell Distribution Width was done for all the 100 patients who met with 
the inclusion criteria and compared with 100 controls. Student t test was 
applied for statistical significance. Patients were followed up and at the 
end of 1 month, outcome was noted for death or hospitalisations during 
that period. 
12 lead ECG was assessed for 
 Ventricular hypertrophy (RVH, LVH) 
 Atrial enlargement 
 Q waves or ST/T changes denoting ischemia or infarction 
 Arrhythmias  
 Conduction blocks 
XRay chest PA view was noted for 
 Pulmonary edema/congestion 
 Cardiomegaly 
 Effusion 
 
M-mode echocardiography was used to assess left ventricle dimensions.  
Following parameters were checked. 
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 LVESD   
 LVEDD.  
 Ejection fraction (Simpson’s method51). 
  Left ventricle end diastole and Left ventricle end systole volumes 
are estimated.  
Fasting plasma glucose was measured using glucose oxidase and 
pyruvate oxidase methods from overnight fasting sample and results were 
read by autoanalyser.2 hr postprandial glucose was measured 2 hrs after 
routine morning breakfast. From patients height and weight, body mass 
index (BMI) was calculated. Serum cholesterol (enzymatic oxidase-
peroxidase method), Serum HDL (polyethylene glycol-CHOD-PAP 
method) Triglycerides (enzymatic calorimetric method) were measured 
using Erba XL 300 autoanalyser. Serum LDL was calculated using 
Friedewald’s formula52.  
Liver function test which included serum bilirubin, transaminases, 
alkaline phosphatase and albumin was done. Serum creatinine was 
measured and  eGFR was calculated using Cockcroft gault equation. 
Ultrasonogram of abdomen was done to look for fatty liver or contracted 
kidneys. Liver disease and renal disease was ruled out. 
Blood samples were collected from antecubital vein using 2cc 
syringe, transferred to an EDTA test tube and analysed in an automated 
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cell counter Sysmex KX21. Hemoglobin,MCV, Hematocrit and RDW 
were determined as part of complete blood count. Normal RDW values: 
RDW-SD—39 to 46 fl 
Risk factors were assessed as follows: 
Diabetes mellitus
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 Blood sugar >126mg/dl after overnight fasting  
 Post prandial blood sugar of 200 mg/dl or greater  
 Symptoms of DM with random glucose 200 mg/dl or greater  
 HbA1C > 6.5% 
 patients already diagnosed and on insulin/ OHAs 
Systemic hypertension  
 systolic BP of 140 mm Hg and above and diastolic BP of 90 mm 
Hg and above ( JNC8) 
 known cases on antihypertensives 
Obesity 
54 
 body mass index > 30 kg/m2 
Dyslipidemia
55
  
 Serum total cholesterol >/= 200 mg/dl (Borderline High) or 
 Serum HDL </= 40 mg/dl(low) or 
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 Serum triglycerides >/= 200 mg/dl (High) or 
 Serum LDL >/= 160 mg/dl(High) (ATP III guidelines) 
Statistical analysis 
SPSS software ver.21.0 was used for calculations using the 
following statistical methods: 
 Independent samples ‘t’ test-unpaired 
 Independent samples ‘t’ test-paired 
 ANOVA 
 Pearson correlation coefficient 
 Turkey kramer’s multiple comparision test 
 Relative risk 
Ethical committee clearance 
The study was approved by the institutional ethical committee of 
our hospital 
Informed consent 
Obtained from all cases and controls 
Conflicts of interest 
None 
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OBSERVATIONS AND RESULTS 
Table 1: AGE INCIDENCE AMONG CASES AND CONTROLS 
Age 
Case Control 
No % No % 
< 20 2 2% 2 2% 
20 – 29 5 5% 5 5% 
30 – 39 15 15% 15 15% 
40 – 49 34 34% 34 34% 
50 – 59 26 26% 26 26% 
60 – 69 16 16% 16 16% 
≥ 70 2 2% 2 2% 
Total 100   100   
 
Among the 100 cases of heart failure selected in our study group, 
34% were in the age group of 40 to 49 years, 26% in the age group of 50 
to 59 years, 16% in the age group of 60 to 69 and 15% in the age group 
30 to 39. 
Figure 1:      Incidence in age
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Table 2: AGE AND SEX INCIDENCE AMONG CASES 
Age Gender 
Case Control 
No % No % 
< 20 
Male 1 1.0% 1 1.0% 
Female 1 1.0% 1 1.0% 
20 - 29 
Male 2 2.0% 2 2.0% 
Female 3 3.0% 3 3.0% 
30 - 39 
Male 9 9.0% 9 9.0% 
Female 6 6.0% 6 6.0% 
40 - 49 
Male 25 25.0% 25 25.0% 
Female 9 9.0% 9 9.0% 
50 - 59 
Male 15 15.0% 15 15.0% 
Female 11 11.0% 11 11.0% 
60 - 69 
Male 10 10.0% 10 10.0% 
Female 6 6.0% 6 6.0% 
≥ 70 
Male 2 2.0% 2 2.0% 
Female 0 0.0% 0 0.0% 
Total 100   100   
 
Figure 2: incidence of heart failure in male and female among various age 
groups 
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In the study group of both cases and controls, 64% were males and 
36% were females. Ratio of male to females was 1.78:1. In both males 
and females, the maximum incidence was seen in the age group 40 to 59 
years with 40 to 49 the maximum in males and 50 to 59 the maximum in 
females. 
 
Table3: VARIOUS ETIOLOGY OF HEART FAILURE AND 
INCIDENCE 
Etiology 
Male Female Total 
No % No % No % 
IHD 31 31.0% 16 16.0% 47 47.0% 
RHD 6 6.0% 8 8.0% 14 14.0% 
Cor pulmonale 8 8.0% 4 4.0% 12 12.0% 
DCM idiopathic 7 7.0% 2 2.0% 9 9.0% 
Alcoholic Cardiomyopathy 3 3.0% 0 0.0% 3 3.0% 
Calcific AS/AR 3 3.0% 1 1.0% 4 4.0% 
Peripartum 0 0.0% 2 2.0% 2 2.0% 
RVD 3 3.0% 1 1.0% 4 4.0% 
Eisenmengers 1 1.0% 1 1.0% 2 2.0% 
Myocarditis 2 2.0% 1 1.0% 3 3.0% 
Total 64 
  
36 
  
100 
  
 
Etiology of heart failure among cases in our study group 
 IHD/CAD  47% 
 RHD     14% 
 COR PULMONALE 12% 
 DCM- CAUSE NOT KNOWN 9% 
 ALCOHOLIC CARDIOMYOPATHY 3% 
63 
 
 CALCIFIC AS/AR 4% 
 PERIPARTUM CARDIOMYOPATHY 2% 
 RVD 4% 
 EISENMENGER’S 2% 
 MYOCARDITIS 3% 
Figure CHART REGARDING ETIOLOGY OF HEART FAILURE 
 
Figure CHART SHOWING ETIOLOGY OF HEART FAILURE  IN 
MALE CASES 
47% 
14% 
12% 
9% 
3% 
4% 
2% 
4% 
2% 
3% 
ETIOLOGY OF HEART FAILURE 
IHD RHD Cor pulmonale
DCM-Cause unknown Alcoholic Cardiomyopathy Calcific AS/AR
Peripartum RVD Eisenmengers
Myocarditis
64 
 
 
 
CHART SHOWING ETIOLOGY OF HEART FAILURE AMONG 
FEMALES 
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Figure COMPARISION OF THE DISTRIBUTION OF CAUSES OF 
HEART FAILURE IN MALES AND FEMALES 
 
TABLE4: RISK FACTORS IN HEART FAILURE PATIENTS 
 
Risk Factors 
Male Female Total 
No % No % No % 
SHT 28 28.0% 12 12.0% 40 40.0% 
DM 23 23.0% 14 14.0% 37 37.0% 
Dyslipidemia 20 20.0% 9 9.0% 29 29.0% 
Smoking 44 44.0% 0 0.0% 44 44.0% 
Alcohol 34 34.0% 0 0.0% 34 34.0% 
 
BMI>30kg/m2 
18 18.0% 15 15.0% 33 33.0% 
Previous H/o 
HF 
13 13.0% 7 7.0% 20 20.0% 
Previous H/o 
MI 
9 9.0% 5 5.0% 14 14.0% 
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Among the 100 cases studied, incidence of risk factors in percentage 
 SHT 40% 
 DM 37% 
 Dyslipidemia 29% 
 Smoking 44% 
 Alcohol 34% 
  BMI>30kg/m2 33% 
 Previous H/o HF 20% 
 Previous H/o MI 14% 
Figure CHART DEPICTING THE MULTIPLE RISK FACTORS 
LEADING TO HEART FAILURE  
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TABLE 5: MAJOR SIGNS AND SYMPTOMS 
Signs& 
Symptoms 
Male Female Total 
No % No % No % 
PND 20 20.0% 12 12.0% 32 32.0% 
Orthopnea 30 30.0% 19 19.0% 49 49.0% 
JVD 28 28.0% 13 13.0% 41 41.0% 
Rales 21 21.0% 12 12.0% 33 33.0% 
S3 17 17.0% 12 12.0% 29 29.0% 
 Edema 27 27.0% 14 14.0% 41 41.0% 
 
Among 100 cases, the spread up of different clinical signs were like this 
 PND  32% 
 Orthopnea  49% 
 JVD  41% 
 Rales 33% 
 S3  29% 
  Edema 41% 
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Figure CHART SHOWING MAJOR SIGNS IN MALES AND 
FEMALES 
 
Table 6: RDW LEVELS IN CASES AND CONTROLS: 
  Case(n=100) Control(n=100) P-Value 
Age 48.25 ± 12.1 48.25 ± 12.1 1 (NS) 
RDW-
SD 
49.9 ± 6.9 42.3 ± 2.3 
< 0.01 
(S) 
 
RDW-SD was studied in 100 cases and equal number of age and 
sex matched controls. Their mean values are compared in the table above.  
The RDW-SD values were highly significant in heart failure patient study 
group when compared to controls. (p<0.01) 
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  Case Control 
RDW-
SD 
49.9 42.3 
 
Figure MEAN RDW LEVELS IN CASES AND CONTROLS 
 
TABLE 7: SHOWING  MEAN RDW-SD LEVELS AMONG 
VARIOUS ETIOLOGY OF HEART FAILURE: 
Etiology 
Mean 
RDW 
IHD 49.9 
RHD 49.9 
Cor 
pulmonale 
52.3 
DCM-Cause 
unknown 
47.3 
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FIGURE : COMPARISION OF RDW LEVELS IN DIFFERENT 
CAUSES OF HEART FAILURE 
RDW-SD levels were compared among different causes of heart 
failure and was found to be high than controls in all causes. This implies 
that RDW-SD levels were elevated in heart failure cases irrespective of 
etiology. 
 
COMPARISION OF RDW LEVELS WITH VARIOUS RISK 
FACTORS 
Then the RDW levels were compared among the different risk 
factors of heart failure. Significant elevations of  RDW were seen in cases 
with risk factors than in cases without risk factors. 
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Table 9:COMPARING RDW AMONG RISK FACTORS IN 
HEART FAILURE: 
 
  Yes No P-Value 
SHT 
53.5 ± 
7.4 
47.3 ± 5.1 < 0.01 (S) 
DM 
53.8 ± 
7.5 
47.7 ± 5.6 < 0.01 (S) 
Dyslipidemia 
56.4 ± 
6.3 
47.2 ± 5.1 < 0.01 (S) 
Smoking 
51.5 ± 
7.4 
48.6 ± 6.2 0.040 (S) 
Alcohol 
52.1 ± 
7.1 
48.7 ± 6.5 0.018 (S) 
 BMI>30kg/m2 
56.0 ± 
6.5 
46.9 ± 4.7 < 0.01 (S) 
 
Among these 100 cases, 10 cases were identified as metabolic 
syndrome based on ATP III guidelines. The mean RDW value among 
those 10 patients was 59.6 ( significantly high) 
 
TABLE 10 : NYHA FUNCTIONAL CLASS AMONG CASES 
NYHA 
Male Female Total 
No % No % No % 
1 4 4.0% 3 3.0% 7 7.0% 
2 10 10.0% 5 5.0% 15 15.0% 
3 37 37.0% 23 23.0% 60 60.0% 
4 13 13.0% 5 5.0% 18 18.0% 
Total 64   36   100   
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Among 100 cases,  
 NYHA Class 1- 7% 
 NYHA Class 2- 15% 
 NYHA Class 3- 60% 
 NYHA Class 4- 18% 
 
FIGURE : NYHA CLASS AMONG HEART FAILURE CASES: 
 
TABLE 11: COMPARISION OF RDW LEVELS AMONG 
DIFFERENT NYHA CLASS 
NYHA RDW-SD P-value 
1 40.2 ± 1.06 
< 0.01 (S) 
2 43.6 ± 2.7 
3 49.1 ± 3.2 
4 61.5 ± 4.03 
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In patients with NYHA class 1 and 2, mean RDW was within 
normal range whereas in class 3 and 4, mean RDW was 49.1 and 61.5 
respectively. RDW levels were compared among 3 groups ie. NYHA 
class 2, 3 and 4 using ANOVA test and was found to be statistically very 
significant. Variation among column means was significantly higher than 
expected by chance. Cases belonging to NYHA class 4 had higher RDW 
levels compared to class 3 and 2.  
TABLE 12. NYHA CLASS- COMPARISION BETWEEN GROUPS 
NYHA 
Mean 
Difference 
P-value 
Class 2 & Class 4 -5.55 < 0.01 (S) 
Class 2 & Class 4 -17.892 < 0.01 (S) 
Class 3 & Class 4 -12.342 < 0.01 (S) 
 
By turkey Kramer multiple comparision test, p value is less than 
0.01. To find out the correlation between NYHA class and RDW, 
Pearson’s coefficient was used with the following results. 
 Correlation coefficient (r) = -0.755 
 Coefficient of determination ( r2) =0.570 
 P value is less than 0.01 which is quite significant. Hence it was 
derived that there is correlation between RDW levels and  
worsening of NYHA functional class. 
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COMPARISION BETWEEN EJECTION FRACTION AND RDW 
LEVELS 
Echo for all heart failure cases was taken and patients were 
classified into 4 groups on the basis of LV ejection fraction. 
 LVEF less than 30% - 26 cases 
 LVEF 30 to 44%  -27 cases 
 LVEF 45 to 54%  -13 cases 
 LVEF greater than 54%  -34 cases 
 
TABLE 13 :SHOWING THE LV EJECTION FRACTION RANGE 
AMONG CASES: 
 
LVEF% 
Male Female Total 
No % No % No % 
< 30 
Severe 
15 15.0% 11 11.0% 26 26.0% 
30 - 44 
Moderate 
19 19.0% 8 8.0% 27 27.0% 
45 - 54 
Mild 
7 7.0% 6 6.0% 13 13.0% 
> 54 
Normal 
23 23.0% 11 11.0% 34 34.0% 
Total 64   36   100   
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FIGURE  CLASSIFICATION ON THE BASIS OF LV EJECTION 
FRACTION
 
The mean RDW among the 4 different groups based on EF values 
were compared. Mean RDW was higher in the group with EF < 30% 
(56.1) when compared with moderate and mild LV dysfunction and was 
normal in the group where EF> 54%. P value was statistically significant 
(less than 0.01) 
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Table 14: COMPARISION OF LV EJECTION FRACTION WITH 
RDW 
 
LVEF RDW-SD P-value 
< 30 
Severe 
56.6 ± 6.1 
< 0.01 (S) 
30 - 44 
Moderate 
51.4 ± 4.7 
45 - 54 
Mild 
50.7 ± 5.4 
> 54 
Normal 
44 ± 3.1 
 
Comparisons were made among the 4 groups based on EF using ANOVA 
test. 
 
TABLE 15: COMPARISION AMONG INDIVIDUAL GROUPS OF 
LV DYSFUNCTION 
LVEF 
Mean 
Difference 
P-value 
Severe & Moderate 6.44 
< 0.01 
(S) 
Severe & Mild 5.138 0.013 (S) 
Severe & Normal 
12.628 
< 0.01 
(S) 
Moderate & Mild -1.302 
0.859 
(NS) 
Moderate & 
Normal 
6.187 
< 0.01 
(S) 
Mild & Normal 7.489 
< 0.01 
(S) 
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By turkey Kramer multiple comparision test, p value is less than 
0.01 when comparing patients with less than 30% EF with the other 
groups. To find out the correlation between EF  and RDW, Pearson’s 
coefficient was used with the following results. 
 Correlation coefficient (r) = 0.640 
 Coefficient of determination ( r2) =0.4096 
P value is less than 0.01 which is quite significant. Hence it was 
derived that there is correlation between  RDW and LV ejection fraction. 
OUTCOME ON FOLLOW UP AT THE END OF ONE MONTH: 
Patients were followed up at the end of 1 month. Among the 100 
patients, 18 were lost in follow up. In the remaining 82 patients, 11 
patients had expired and 13 had been hospitalised for  failure symptom 
exacerbation. 
TABLE 15: OUTCOME AT THE END OF 1 MONTH 
Outcome after 
one month 
Male Female Total 
No % No % No % 
Death 11 11% 4 4% 15 15% 
Hospitalised 13 13% 12 12% 25 25% 
Lost in Followup 13 13% 5 5% 18 18% 
Non Hospitalised 27 27% 15 15% 42 42% 
Total 64   36   100   
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FIGURE  SHOWING OUTCOME AT END OF 1 MONTH 
The mean RDW  of the three categories of  patients on the basis of 
outcome was derived and was found to be significantly higher in patients 
who died at  the end of 1 month ie. 61.3. Mean RDW of those who were 
hospitalised for symptoms during that 1 month was also higher when 
compared to those without hospitalisation. P value was very 
significant(less than 0.01) 
Outcome after one month RDW Mean 
Death 61.3 
Hospitalised 51.6 
Non Hospitalised 46.7 
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FIGURE  SHOWING  OUTCOME AT THE END OF 1 MONTH 
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DISCUSSION 
Elevated red cell distribution width has been found to be associated 
for a long time with increased risk of  adverse cardiovascular event in 
heart failure patients. Although the exact mechanism behind this is not 
clearly known, several postulates have been contemplated by researchers 
across the globe. Inflammation and oxidative stress have been considered 
as the principal reason behind the alteration in erythrocyte homeostasis. 
Proinflammatory cytokines
56
 like IL-6
40,TNFα and IL-1β 
erythropoietin mediated RBC maturation leading to increased in RDW. 
Bone marrow resistance to erythropoietin, deranged iron metabolism, 
hemodilution and anemia of chronic disease have been proposed as 
mechanism for anemia
57
 and increased mortality in heart failure patients.  
Although many studies have successfully elucidated the prognostic role 
of RDW in heart failure, no clear insights into the mechanisms behind the 
same have been arrived till date. CHARM data and Duke Databank were 
used to study the role of RDW as a prognostic marker in heart failure
58
. 
Increased RDW is associated with metabolic syndrome, renal 
impairment, carotid artery atherosclerosis ,older age and in critically ill 
patients. Including natriuretic peptides and few other costly markers 
along with the cheaper RDW has helped in establishing the role of RDW 
as an independent marker in the prognosis of heart failure. 
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100 patients with heart failure ( inpatients as well as out patients 
attending our hospital) were selected after exclusion criteria and 100  
controls with no comorbidities were also identified . Red Cell 
Distribution Width was measured in all these people. 
The mean age group of patients with heart failure  as well as 
control was 48.25 years with the minimum age of 17 years and maximum 
of 74 years. 64% were males and 36% were females. Ratio of male to 
females was 1.78:1. In both males and females, the maximum incidence 
was seen in the age group 40 to 59 years with 40 to 49 the maximum in 
males and 50 to 59 the maximum in females.  
The mean RDW-SD were compared between cases and 
controls.49.9 in cases and 42.3 in controls. The RDW-SD values were 
highly significant in heart failure patient study group when compared to 
controls. (p<0.01) 
IHD accounted for the major chunk of the cases comprising 47% of 
cases. The 2
nd
 common cause in our study population was RHD with 
DCM and cor pulmonale ranking down the order.  Mean RDW among 
various causes ranged between 47.3 in DCM, 49.9 in IHD and RHD and 
52.3 in cor pulmonale. This implies that RDW-SD levels were elevated in 
heart failure cases irrespective of etiology. 
82 
 
RDW was significantly elevated in heartfailure patients with 
additional risk factors like hypertension, diabetes and dyslipidemia. Mean 
RDW was 56.4 in patients with dyslipidemia and 56 in patients with BMI 
>30kg/m
2
. Even in controls mean RDW was on the higher side 46.9 in 
obese individuals. Among  100 cases, 10 cases were identified as 
metabolic syndrome based on ATP III guidelines. The mean RDW value 
among those 10 patients was 59.6 ( significantly high) .ICARIA 
(Ibermutuamur Cardiovascular Risk Assessment study ) observed that 
RDW is associated with metabolic syndrome.They stated that a cutoff of 
13.5 for RDW-CV in metabolic syndrome. 
In patients with NYHA class 1 and 2, mean RDW was within 
normal range whereas in class 3 and 4, mean RDW was 49.1 and 61.5 
respectively. Cases belonging to NYHA class 4 had higher RDW levels 
compared to class 3 and 2. RDW levels were compared among 3 groups 
ie. NYHA class 2, 3 and 4 using ANOVA test and was found to be 
statistically very significant. Pearson’s coefficient was used with 
Correlation coefficient (r) = -0.755 and derived that there is correlation 
between RDW levels and  worsening of NYHA functional class. 
Echo revealed 26 persons with EF less than 30%, 27 persons with 
EF between 30% and 44%, 13 persons with EF between 45% and 54%  
and 34 persons with EF above 54% .The mean RDW among the 4 
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different groups based on EF values were compared. Mean RDW was 
higher in the group with EF < 30% (56.1) when compared with moderate 
and mild LV dysfunction and was normal in the group where EF> 54%. P 
value was statistically significant (less than 0.01).correlation coefficient 
(r) was 0.640. Hence it was concluded that there is correlation between  
RDW and LV ejection fraction.   
Patients were followed up at the end of 1 month. Among the 100 
patients, 18 were lost in follow up. In the remaining 82 patients, 11 
patients had expired and 13 had been hospitalised for  failure symptom 
exacerbation. The mean RDW  of the three categories of  patients on the 
basis of outcome was derived and was found to be significantly higher in 
patients who died at  the end of 1 month ie. 61.3. mean RDW of those 
who were hospitalised for symptoms during that 1 month was also higher 
when compared to those without hospitalisation. P value was very 
significant(less than 0.01). 
All our observations revealed that RDW can be used as a cheaper 
and easily available prognostic marker in heart failure patients. This was 
in concordance with several studies done in various other centres globally 
which revealed higher mortality rates with elevated RDW levels.  
Kimmenade et al.
59
 followed up an acute HF cohort of 205 patients  
over a period of 12 months  for all cause mortality. 31% patients died at 
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the end of 1 year. Rates of mortality are higher with increased RDW. 
They suggested that RDW was a significant independent predictor of one 
year outcome in acute HF.  
In another heart failure cohort studied by Felker et al
44
, highest 
RDW quintile (15.5%) had a two fold elevated risk of mortality. 
SENIORS study
60
 results revealed anemia as an independent 
marker of death or hospitalisation in elderly chronic heart failure patients. 
A study of laboratory parameters  and outcomes using Cox 
proportional hazards model  in 2679 HF patients from CHARM program 
and 2140 HF patients from Duke Databank revealed  RDW as a strong 
and independent predictor of morbidity and mortality. 
2 groups of CAD patients, one with RDW>13.8%  vs another with 
RDW<12.6% were studied by Tonelli
61
 et al. and was found that death 
was twice likely in the former group.  
In summary, our study found that increased RDW was associated 
with increased incidence of heart failure. Elevated RDW is a predictor of 
all cause mortality in HF patients 
62
. Though many trials are going on in 
the management aspect of anemia in HF,  only time and further research 
might reveal if correction of anemia with hematopoietic agents may show 
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improvement in RDW and in turn in the improvement of the functional 
class of  HF and cause a reduction in mortality. 
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LIMITATIONS OF THE STUDY 
 Small sample size 
 Short follow up of only 1 month-  a 1 year or 2 year 
follow up program would have resulted in better assessment of  
outcome. 
 Though anemia in the form of reduced haemoglobin 
or renal disease leading to anemia were excluded from the 
study,B12 and folate deficiency anemia were not absolutely ruled 
out (inspite of normal range of MCV where significant deficiencies 
can be ruled out safely). 
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CONCLUSION 
 Red Cell Distribution Width( RDW) levels  are  
increased in heart failure patients than in healthy controls 
 Heart failure patients with higher NYHA class  have 
elevated RDW levels. Thus RDW levels correlated with NYHA 
class of HF. 
 Heart failure patients with low LV ejection fraction 
have elevated RDW levels compared with normal LV ejection 
fraction, thus RDW levels correlated with severity of LV 
dysfunction. 
 RDW can be not just a marker but a strong predictor 
of mortality in heart failure patients. 
 Combining RDW with other biomarkers and NYHA 
functional class can indeed be a very good predictor of morbidity 
and mortality. 
 Therapy of anemia in heart failure with resultant 
increase in RDW can aid in a favourable outcome which further 
requires a lot of prospective studies. 
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EVALUATION OF RED CELL DISTRIBUTION WIDTH IN 
HEART FAILURE  PATIENTS : PROFORMA 
Name:      Age/Sex: 
Address:      Occupation: 
Symptoms: 
 Shortness of breath NYHA class 
 Orthopnoea 
 PND 
 Chest pain 
 Swelling of legs  
 Easy fatiguability 
 Palpitations 
 Nocturnal cough 
Past history: 
Diabetes mellitus 
Hypertension 
Coronary artery disease 
Heart failure 
Previous hospitalizations for heart failure 
Previous CPR 
Liver disease 
Kidney disease 
Tuberculosis 
Blood transfusions in the past 
Iron/folate/ B12 replacement therapy 
Other co morbid illnesses 
Personal history: 
 Smoking 
 Alcoholism 
Vitals:   PULSE:                   BLOOD PRESSURE: 
General examination: 
 Icterus 
 Pallor 
 Pedal edema 
 JVP 
 lymphadenopathy 
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Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
 
Investigations: 
RFT LFT 
Glucose  mg/dl Total bilirubin  mg/dl 
Urea  mg/dl Direct 
bilirubin 
 mg/dl 
Creatinine  mg/dl SGOT  U/l 
Na+  mEq/l SGPT  U/l 
K+  mEq/l ALP  U/l 
  Total protein  g/dl 
  Albumin  g/dl 
Fasting lipid profile: 
 
Chest X-ray: 
 
 
ECG: 
 
 
Echocardiography: 
 
 
 
 
 
Ultrasound abdomen: 
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COMPLETE BLOOD COUNT 
 
 
  
INVESTIGATIONS   
 WBC 103/µL  
 RBC 106/µL  
 Hemoglobin gm/Dl  
 HCT %  
 MCV Fl  
 MCH Pg  
 MCHC gm/dL  
 Platelet Count 103/µL  
 Lymphocyte % %  
 Mixed % (Basophilis, Eosinophils) %  
 Neutrophil % %  
 Lymphocyte # 103/µL  
 Mixed # 103/µL  
 Neutrophil # 103/µL  
 Red cell distribution width  fL  
 Platelet distribution width fL  
 Mean Platelet volume fL  
 P- LCR (large platelet ratio) %  
Peripheral smear  
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1 Dinakaran 69 M 13.2 39.8 86.1 46.3 Y N N N N N N N N N 
2 Udhayakumar 66 M 12.3 37.6 84.9 49.6 Y N N N N N N N N N 
3 Rajan 66 M 13.2 40.5 98.3 55.5 Y N N N N N N N N N 
4 Prabhakaran 63 M 13 44.3 85.5 65.6 Y N N N N N N N N N 
5 Murugesan 65 M 14.1 41.1 96.3 51.1 Y N N N N N N N N N 
6 Iqbal 60 M 13.4 40.5 84.2 42.4 Y N N N N N N N N N 
7 Murugan 50 M 12.3 38.1 90.1 49.6 Y N N N N N N N N N 
8 Kumar 54 M 14.1 42 93.2 50.3 Y N N N N N N N N N 
9 Johnson 53 M 12.7 37.8 86.7 44.2 Y N N N N N N N N N 
10 Ravi 57 M 12.4 42.8 94.7 65.9 Y N N N N N N N N N 
11 Gopi 58 M 12.8 37.4 95.4 49.3 Y N N N N N N N N N 
12 Vinayagam 59 M 14.2 43.8 88.8 40.3 Y N N N N N N N N N 
13 Anthony 52 M 12 37 92.5 48.2 Y N N N N N N N N N 
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14 Manigandan 28 M 14 44.6 79.6 48.4 Y N N N N N N N N N 
15 Ramesh 33 M 12.1 33.8 89.2 44.6 Y N N N N N N N N N 
16 Vijay 34 M 16 48 103.9 58.8 Y N N N N N N N N N 
17 Venu 40 M 13 40 99 55.9 Y N N N N N N N N N 
18 Mohammad faisil 41 M 12 36 91.9 58.4 Y N N N N N N N N N 
19 Subramani 45 M 13.5 42 92.9 48.6 Y N N N N N N N N N 
20 Prasad 43 M 12.5 37 85.1 50.6 Y N N N N N N N N N 
21 Srinivasan 47 M 12.8 44 87.8 43.8 Y N N N N N N N N N 
22 Rangaraj 46 M 13.5 41 92.4 51.2 Y N N N N N N N N N 
23 Maniappan 43 M 12.4 37 88.2 46.8 Y N N N N N N N N N 
24 Ayyanar 44 M 12.6 38 85.1 41.5 Y N N N N N N N N N 
25 Albert 49 M 12.6 36.2 85.6 40.6 Y N N N N N N N N N 
26 Kondaiah 48 M 13.8 41.4 88.1 45.9 Y N N N N N N N N N 
27 Rajamundri 49 M 12.8 40.2 91.4 48 Y N N N N N N N N N 
28 Krishnan 47 M 12.2 38 94.5 46.2 Y N N N N N N N N N 
29 Tamilselvan 48 M 12.9 39 91.8 56 Y N N N N N N N N N 
30 Syed 55 M 12.3 37 86 49.4 Y N N N N N N N N N 
31 Manoj 77 M 13.2 39.1 94.8 49.7 Y N N N N N N N N N 
32 Ayappan 17 M 12.6 38.1 83.4 42.9 N Y N N N N N N N N 
33 Ilayaraja 25 M 13.3 39.3 84.4 45.3 N Y N N N N N N N N 
34 Vignesh 34 M 13.5 40.1 91 59.4 N Y N N N N N N N N 
35 Devaraj 36 M 15.1 45.1 95.8 47.8 N Y N N N N N N N N 
36 Vickram 38 M 15.6 46.5 87.7 48.3 N Y N N N N N N N N 
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37 Elumalai 40 M 12.4 37.3 81.3 41.8 N Y N N N N N N N N 
38 Ellapan 55 M 12.4 37 88.2 46.8 N N Y N N N N N N N 
39 Chinnapaiyan 57 M 15.8 48 99 54.7 N N Y N N N N N N N 
40 Kaliappan 50 M 14.9 45 98.4 68.2 N N Y N N N N N N N 
41 Periyasamy 48 M 13.7 40.5 83.9 44.3 N N Y N N N N N N N 
42 Raju 49 M 14.1 41.3 95.9 51.3 N N Y N N N N N N N 
43 Anandan 45 M 15.3 45.6 100.9 61.8 N N Y N N N N N N N 
44 Nagoormeeran 43 M 12.7 38.1 87.8 51.2 N N Y N N N N N N N 
45 Franklin 37 M 13.5 40.1 91 59.4 N N Y N N N N N N N 
46 Ganesan 64 M 12.6 38.3 94.5 45.9 N N N Y N N N N N N 
47 Sivaraman 60 M 12.2 36.9 83.4 44.3 N N N Y N N N N N N 
48 Arumugam 59 M 12.7 37.3 91.8 56 N N N Y N N N N N N 
49 Arokkiayasamy 51 M 12.9 38.4 94.8 49.7 N N N Y N N N N N N 
50 Rajakumar 40 M 12.5 38.5 91.8 60.2 N N N Y N N N N N N 
51 Selvaraj 48 M 12.1 36.7 84.7 41 N N N Y N N N N N N 
52 Aravindan 43 M 12.2 34.8 88.3 39.3 N N N Y N N N N N N 
53 Munusamy 37 M 15.4 46.1 96.7 47.9 N N N N Y N N N N N 
54 Rangasamy 45 M 13.8 41.8 82.3 41.8 N N N N Y N N N N N 
55 Suresh 52 M 12.7 38.1 87.8 51.2 N N N N Y N N N N N 
56 Kanappan 66 M 12.6 37.7 91.8 58.2 N N N N N Y N N N N 
57 Pandian 70 M 12.8 39 84.5 46.8 N N N N N Y N N N N 
58 Mani 65 M 13.1 39 98 66.5 N N N N N Y N N N N 
59 Kabilan 44 M 13 38.7 86 47 N N N N N N N Y N N 
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60 Peer Mohammad 40 M 12.1 39 86.7 46.5 N N N N N N N Y N N 
61 Saravanan 35 M 12.4 37.2 88.1 45 N N N N N N N Y N N 
62 Kamalakannan 33 M 12.7 38.1 87.8 50.2 N N N N N N N N Y N 
63 Venketesan 47 M 13.9 42.1 91.5 44.5 N N N N N N N N N Y 
64 Nataraj 53 M 12 36.8 82 39.4 N N N N N N N N N Y 
65 Shanthi 59 F 13.4 39.3 84.5 45.3 Y N N N N N N N N N 
66 Nagammal 63 F 12.7 38.1 87.8 51.2 Y N N N N N N N N N 
67 Rani 66 F 12.3 37 86 49.4 Y N N N N N N N N N 
68 Devamala 62 F 12.4 37.3 84 58.1 Y N N N N N N N N N 
69 Kuppamal 60 F 12.2 36.9 83.4 44.3 Y N N N N N N N N N 
70 Kaniammal 67 F 12.1 36.5 92.5 68 Y N N N N N N N N N 
71 Anjalai 58 F 12.3 37.4 89.7 53 Y N N N N N N N N N 
72 Manjula 59 F 12 36.5 86.9 53.2 Y N N N N N N N N N 
73 Shaheeda 53 F 12.9 38.4 94.8 49.7 Y N N N N N N N N N 
74 Syndhia 54 F 12.1 36.7 84.7 41 Y N N N N N N N N N 
75 Angammal 56 F 12.5 38.5 91.8 60.2 Y N N N N N N N N N 
76 Parvathy 55 F 12.6 38.4 94.7 45.9 Y N N N N N N N N N 
77 Malleswari 53 F 13 40 99.8 55.9 Y N N N N N N N N N 
78 Chandra 46 F 12.6 38.1 86.5 46.5 Y N N N N N N N N N 
79 Muniammal 48 F 12.6 38.1 83.7 42.9 Y N N N N N N N N N 
80 Parveen Beevi 44 F 12.2 34.8 88.3 39.3 Y N N N N N N N N N 
81 Mookammal 45 F 13.3 39 83.6 47 N Y N N N N N N N N 
82 Chinammal 43 F 13.1 39.3 97 54 N Y N N N N N N N N 
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83 Revathy 32 F 13 36.9 87 50.6 N Y N N N N N N N N 
84 Kamatchi 38 F 12.8 36.2 87.7 55.9 N Y N N N N N N N N 
85 Saroja 34 F 12.6 38.1 83.7 43.7 N Y N N N N N N N N 
86 Kanthammal 33 F 12.8 37.1 91.5 48.7 N Y N N N N N N N N 
87 Selvi 25 F 15.6 46.7 87.6 48.3 N Y N N N N N N N N 
88 Devagi 17 F 12.4 36.7 94.6 65.3 N Y N N N N N N N N 
89 Vasantha 48 F 13.2 41.3 87.1 43.4 N N Y N N N N N N N 
90 Rajeswari 42 F 12.3 36.1 95.8 47.8 N N Y N N N N N N N 
91 Kavitha 47 F 12.9 39 93.1 56 N N Y N N N N N N N 
92 Seethammal 53 F 13.5 42.3 93.1 48.6 N N Y N N N N N N N 
93 Vijaya 48 F 12.8 40.9 87.8 43.8 N N N Y N N N N N N 
94 Fathima 56 F 12.2 38 94.7 45.9 N N N Y N N N N N N 
95 Alicia 66 F 12.3 38.3 89.3 50.3 N N N N N Y N N N N 
96 Mariammal 27 F 12.1 37.3 87.9 46.5 N N N N N N Y N N N 
97 Velvizhi 33 F 12.7 38.1 87.8 51.1 N N N N N N Y N N N 
98 Mary 35 F 13.5 41.2 92.4 51.2 N N N N N N N Y N N 
99 Umarani 27 F 12.4 39.3 93.7 60.5 N N N N N N N N Y N 
100 Raniammal 58 F 12 36.7 82 39.4 N N N N N N N N N Y 
101 Sivakumar 69 M 12.3 36.2 84.6 41.8 N N N N N N N N N N 
102 Devendran 66 M 12.6 38.3 87 45.1 N N N N N N N N N N 
103 Chandran 66 M 12.6 36.1 80.3 36.8 N N N N N N N N N N 
104 Vijayan 63 M 12.6 38.8 85.5 42.9 N N N N N N N N N N 
105 Baskar 65 M 12.7 39.6 83 41.7 N N N N N N N N N N 
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106 Diwakar 60 M 12.3 37.5 82 41.5 N N N N N N N N N N 
107 Nagaraj 50 M 12.4 37.5 86.4 42.5 N N N N N N N N N N 
108 Kuppan 54 M 12.9 40.4 83.8 41.8 N N N N N N N N N N 
109 Chinnathambi 53 M 13.8 41.2 81.9 42.2 N N N N N N N N N N 
110 Ravanaiah 57 M 12.1 37 83.7 44.4 N N N N N N N N N N 
111 Chellapan 58 M 13.3 39 78.5 47 N N N N N N N N N N 
112 Pitchaiyah 59 M 12.5 37.3 81.3 41.8 N N N N N N N N N N 
113 Velan 52 M 12.7 35.8 85.6 40.6 N N N N N N N N N N 
114 Narayanan 28 M 12.6 36.2 77.4 39.7 N N N N N N N N N N 
115 Thangaraj 33 M 12.2 34.8 88.3 39.3 N N N N N N N N N N 
116 Chelladurai 34 M 12.2 37.8 80.8 41.9 N N N N N N N N N N 
117 Ashokan 40 M 12.2 35.4 83.7 45.2 N N N N N N N N N N 
118 Ponnusamy 41 M 12.4 37.5 86.4 42.5 N N N N N N N N N N 
119 Pitchandi 45 M 12.3 36.5 82.3 42.4 N N N N N N N N N N 
120 Zaheer 43 M 12.6 36.2 83.2 40.8 N N N N N N N N N N 
121 Aruldasan 47 M 12 36.8 82 39.4 N N N N N N N N N N 
122 Kumaravel 46 M 12.9 37.6 86.7 43.5 N N N N N N N N N N 
123 Durairaj 43 M 12.6 36.3 83.5 40.9 N N N N N N N N N N 
124 Gokulan 44 M 12.2 37.8 80.9 41.3 N N N N N N N N N N 
125 Hariharan 49 M 12.7 36.3 87 40.6 N N N N N N N N N N 
126 Poongavanan 48 M 13.8 41.4 88.3 45.9 N N N N N N N N N N 
127 Shankar 49 M 12.2 34.8 89.1 39.4 N N N N N N N N N N 
128 Venkatiah 47 M 12.6 36.7 83.3 39.7 N N N N N N N N N N 
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129 Samikannu 48 M 13.6 40.6 92.3 43.2 N N N N N N N N N N 
130 Francis 55 M 12.7 39.6 87 42.1 N N N N N N N N N N 
131 Ganapathy 77 M 12.6 38.3 87.3 45.1 N N N N N N N N N N 
132 Narasimhan 17 M 13.3 39 78.5 47 N N N N N N N N N N 
133 Damu 25 M 13.9 42.1 91.6 44.5 N N N N N N N N N N 
134 Ahmad 34 M 12.3 36.3 84.7 41.8 N N N N N N N N N N 
135 Nayagam 36 M 12.6 36.3 83.2 36.7 N N N N N N N N N N 
136 Jeyaraj 38 M 12.7 38.8 88.5 42.3 N N N N N N N N N N 
137 Deenadayalan 40 M 12.7 39.6 87 40.7 N N N N N N N N N N 
138 Sukumar 55 M 15.9 48 82.9 41.3 N N N N N N N N N N 
139 Kannaiah 57 M 14 44.6 89.7 48.4 N N N N N N N N N N 
140 Palaniappan 50 M 13.8 41.8 82.3 41.8 N N N N N N N N N N 
141 Appasamy 48 M 12.7 39.3 84.3 41.2 N N N N N N N N N N 
142 Manickam 49 M 12.8 39 87.8 43.8 N N N N N N N N N N 
143 Surendar 45 M 12.2 37.3 94.5 45 N N N N N N N N N N 
144 Sathyan 43 M 13.5 42 92.3 46 N N N N N N N N N N 
145 Umashankar 37 M 12.6 38.1 83.4 42.9 N N N N N N N N N N 
146 Vadivel 64 M 12.3 37.3 85.6 43.2 N N N N N N N N N N 
147 Ravindran 60 M 12.5 37.6 86 44.3 N N N N N N N N N N 
148 Balaji 59 M 13.5 40.1 82.3 40.9 N N N N N N N N N N 
149 Kuppaiah 51 M 12.9 38.7 83 42.7 N N N N N N N N N N 
150 Dhanasekar 40 M 13.3 41.1 85.6 43.2 N N N N N N N N N N 
151 Raman 48 M 12.1 36 86.1 43.1 N N N N N N N N N N 
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152 Kamalasekar 43 M 12.2 36.9 84.7 41 N N N N N N N N N N 
153 Prabhu 37 M 12.6 38.3 88.7 41.5 N N N N N N N N N N 
154 Raju 45 M 12.6 37 85.8 44.3 N N N N N N N N N N 
155 Napolean 52 M 12.9 38.5 94.8 47 N N N N N N N N N N 
156 Nirmal 66 M 12.7 37.3 89.2 44.6 N N N N N N N N N N 
157 Sundar 70 M 12.5 37.5 87.1 39.6 N N N N N N N N N N 
158 Shakthivel 65 M 13.3 39.7 92.4 43.5 N N N N N N N N N N 
159 Rajeev kumar 44 M 12.5 38.4 88.7 41.5 N N N N N N N N N N 
160 Samsuddin 40 M 12.1 36.7 84.7 41 N N N N N N N N N N 
161 Thanmbaiah 35 M 12.9 38.4 87 43.3 N N N N N N N N N N 
162 Jegadeesan 33 M 13.3 39.3 87.7 45.3 N N N N N N N N N N 
163 Balasubramani 47 M 12.7 38 87.8 43.2 N N N N N N N N N N 
164 Madhivanan 53 M 12.3 36.1 84.6 41.8 N N N N N N N N N N 
165 Madhavi 59 F 13.2 37.4 88.8 40.3 N N N N N N N N N N 
166 Shaheena 63 F 12.6 38.3 83.7 39.7 N N N N N N N N N N 
167 Gnanapriya 66 F 12.6 37.1 84 36.8 N N N N N N N N N N 
168 Malliga 62 F 12.9 40.4 83.8 45.1 N N N N N N N N N N 
169 Anthoniammal 60 F 12.7 39.6 83.3 41.5 N N N N N N N N N N 
170 Saraswathy 67 F 13.8 42.1 91.5 44.5 N N N N N N N N N N 
171 Masthan 58 F 12.4 37.5 86.4 42.5 N N N N N N N N N N 
172 Muthulaksmi 59 F 13.6 40.2 92.2 43.2 N N N N N N N N N N 
173 Indradevi 53 F 13.8 41.7 98.1 41.7 N N N N N N N N N N 
174 Mangammal 54 F 12.1 37 82.9 44.4 N N N N N N N N N N 
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175 Pavithra 56 F 12.2 35.9 83.9 40.7 N N N N N N N N N N 
176 Samithai 55 F 12.8 39.4 87 41.5 N N N N N N N N N N 
177 Gajalaksmi 53 F 12.4 38.4 84.3 43.2 N N N N N N N N N N 
178 Haripriya 46 F 12.2 35.3 83.6 45.2 N N N N N N N N N N 
179 Valli 48 F 12.5 38.5 81.3 42.4 N N N N N N N N N N 
180 Poongodi 44 F 12.2 34.8 84.3 39.3 N N N N N N N N N N 
181 Sadayammal 45 F 12.2 35.4 83.7 45.2 N N N N N N N N N N 
182 Pachayammal 43 F 12.6 36.2 87.4 39.7 N N N N N N N N N N 
183 Devi 32 F 12.7 35.8 85.6 40.7 N N N N N N N N N N 
184 Kasthuri 38 F 13.2 40.2 87.1 43.4 N N N N N N N N N N 
185 Thulasi 34 F 12.8 40.1 82.9 45.3 N N N N N N N N N N 
186 Shanmugapriya 33 F 12.1 37.1 84.1 42.3 N N N N N N N N N N 
187 Chithra 25 F 13.5 41.1 86.3 41.6 N N N N N N N N N N 
188 Janani 17 F 12 37 92.5 43.1 N N N N N N N N N N 
189 Sureka 48 F 12.6 38.3 87 45.1 N N N N N N N N N N 
190 Subammal 42 F 12.7 37.6 86.5 44.2 N N N N N N N N N N 
191 Thangammal 47 F 13.4 40.5 86.1 40.3 N N N N N N N N N N 
192 Saritha 53 F 12.2 35.8 87.3 39.3 N N N N N N N N N N 
193 Rita 48 F 12.8 37.8 84.6 40.6 N N N N N N N N N N 
194 Kannagi 56 F 12.9 38.1 87.3 37.9 N N N N N N N N N N 
195 Vimala 66 F 13.8 42.1 87.3 41.8 N N N N N N N N N N 
196 Padmavathy 27 F 13.8 41.4 82.3 42.2 N N N N N N N N N N 
197 Pushpavathy 33 F 13.3 39 87.7 42.2 N N N N N N N N N N 
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198 Latha 35 F 12.4 38.8 81.5 42.5 N N N N N N N N N N 
199 Usha 27 F 12.7 37.4 91.4 41.4 N N N N N N N N N N 
200 Esther 58 F 12.6 38.1 83.4 39.1 N N N N N N N N N N 
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1 Dinakaran 69 M N N N y y N N N 3 N N N N N N 58 L 
2 Udhayakumar 66 M N y N y y N N N 3 N N N N N y 49 S 
3 Rajan 66 M y y N y y y y N 3 y y y y y y 44 L 
4 Prabhakaran 63 M y y y y y y y y 4 y y y y y y 25 D 
5 Murugesan 65 M N y y N y N N N 3 N y y N N N 30 H 
6 Iqbal 60 M N N N y N N N N 2 N N N N N N 60 L 
7 Murugan 50 M N y N N N N N N 3 N N N N N N 28 H 
8 Kumar 54 M y N y y y N y y 3 N y y y N y 44 S 
9 Johnson 53 M y N N N N N N N 3 N N N N N N 57 S 
10 Ravi 57 M y N y y y y y N 4 y y y y y y 29 D 
11 Gopi 58 M N N N y N N N N 3 N N N N N N 44 S 
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12 Vinayagam 59 M N y N y N N N N 2 N N N N N N 56 S 
13 Anthony 52 M y y N N N y y N 3 N N N N N N 48 S 
14 Manigandan 28 M N N N y y N N N 3 N y N N N N 33 H 
15 Ramesh 33 M y y N N N N N N 3 N N N N N N 41 L 
16 Vijay 34 M y N y y y y N y 4 y y y y y y 24 D 
17 Venu 40 M N y y y N N y y 3 y y y y y y 29 H 
18 Mohammad faisil 41 M y y y y y y y N 4 y y y y y y 25 D 
19 Subramani 45 M N N N y y N N N 3 N N N N N N 29 H 
20 Prasad 43 M y N y y N N N y 3 y y y y N y 56 L 
21 Srinivasan 47 M N y N N y N N N 2 N N N N N N 58 S 
22 Rangaraj 46 M N N y y y y N y 3 y y y y N y 22 H 
23 Maniappan 43 M y N N N y N N N 2 N N N N N N 59 S 
24 Ayyanar 44 M y N N y N N N N 2 N N N N N N 56 S 
25 Albert 49 M N N N y N N N N 2 N N N N N N 61 L 
26 Kondaiah 48 M y N N y y N N y 3 N N N N N N 55 S 
27 Rajamundri 49 M N N N y y y N N 3 N N y N N N 33 S 
28 Krishnan 47 M N N N y y N N N 3 N N N N N N 52 S 
29 Tamilselvan 48 M y y y y N y y y 4 y y y y y y 22 D 
30 Syed 55 M y N N y N y N N 3 N y y N N N 39 S 
31 Manoj 77 M y N N N N N N N 3 N y y N N N 42 S 
32 Ayappan 17 M N N N N N N N N 2 N N N N N N 59 L 
33 Ilayaraja 25 M N N N N N N N N 3 N N N N N N 57 L 
34 Vignesh 34 M N N y y y y y N 4 y y y y y y 38 H 
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35 Devaraj 36 M N N N N y N N N 3 N N N N N N 38 S 
36 Vickram 38 M N N N y N N N N 3 N y y N N y 43 L 
37 Elumalai 40 M y N N N N N N N 1 N N N N N N 62 L 
38 Ellapan 55 M N N N N y N N N 3 N y N N N N 57 S 
39 Chinnapaiyan 57 M y y N y N N N N 3 y y y y y y 29 D 
40 Kaliappan 50 M y y y y y y y N 4 y y y y y y 33 D 
41 Periyasamy 48 M N N N N N N N N 2 N N N N N N 60 S 
42 Raju 49 M N y N y y N N N 3 y y y y y y 40 L 
43 Anandan 45 M y N y y y y N y 4 y y y y y y 25 H 
44 Nagoormeeran 43 M y y N y N N N N 2 N y N N N y 36 H 
45 Franklin 37 M y y y y y y y N 4 y y y y y y 51 H 
46 Ganesan 64 M y N N y N N N N 3 N N N N N N 35 H 
47 Sivaraman 60 M N N N N y N N N 3 N N y N N N 60 S 
48 Arumugam 59 M y y y y y y N N 4 y y y y y y 27 D 
49 Arokkiayasamy 51 M y y N y N y N N 3 N y y N N y 23 H 
50 Rajakumar 40 M y y y y y N y N 4 y y y y y y 27 D 
51 Selvaraj 48 M N N N N N N N N 1 N N N N N N 60 S 
52 Aravindan 43 M N N N N N N N N 1 N N N N N N 66 S 
53 Munusamy 37 M N N N N y N y N 3 N N N N N y 59 S 
54 Rangasamy 45 M N N N y y N N N 2 N N N N N N 63 L 
55 Suresh 52 M N y y y y y N N 3 y y y y N y 38 H 
56 Kanappan 66 M y y y N y N N N 4 y y y y y y 42 D 
57 Pandian 70 M N N N y N N N N 3 N N N N N N 53 S 
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58 Mani 65 M y y y y N y N N 4 y y y y y y 24 D 
59 Kabilan 44 M N N N y y N N N 3 N N N N N N 49 S 
60 Peer Mohammad 40 M N N N y y N N N 3 N N N N N N 61 S 
61 Saravanan 35 M N N N y y N N N 3 N N N N N N 60 S 
62 Kamalakannan 33 M N N N y N N N N 3 N y N N N y 45 S 
63 Venketesan 47 M N N y N N N N N 3 N N N N N N 40 S 
64 Nataraj 53 M N N N y N N N N 1 N N N N N N 62 L 
65 Shanthi 59 F y N y N N N N N 3 N N N N N N 56 S 
66 Nagammal 63 F y N y N N y y N 3 y y y y y y 48 S 
67 Rani 66 F N y N N N N N N 3 N N N N N N 29 H 
68 Devamala 62 F y y N N N y y y 4 y y y y y y 28 D 
69 Kuppamal 60 F N N N N N N N N 2 N N N N N N 62 S 
70 Kaniammal 67 F y y N N N y y N 4 y y y y y y 29 D 
71 Anjalai 58 F N N N N N y N y 3 y y y y y y 28 H 
72 Manjula 59 F y N y N N y N y 3 y y y y y y 26 H 
73 Shaheeda 53 F N y y N N N N N 3 N y N N N y 26 H 
74 Syndhia 54 F N N N N N N N N 1 N N N N N N 65 L 
75 Angammal 56 F y y y N N y y y 4 y y y y y y 27 D 
76 Parvathy 55 F N N N N N N N N 3 N N N N N N 43 S 
77 Malleswari 53 F y N y N N y N y 3 y y y y y N 29 H 
78 Chandra 46 F N y N N N y N N 3 N N N N N N 38 H 
79 Muniammal 48 F y N N N N N N N 2 N N N N N N 33 H 
80 Parveen Beevi 44 F N N N N N N N N 1 N N N N N N 64 L 
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81 Mookammal 45 F N N N N N N N N 3 N N N N N N 59 S 
82 Chinammal 43 F N N N N N N N N 3 y y y y y y 50 L 
83 Revathy 32 F N y N N N N N N 3 N y N N N y 57 S 
84 Kamatchi 38 F y N N N N y y N 3 y y y y y y 50 S 
85 Saroja 34 F N N N N N N N N 2 N N N N N N 58 S 
86 Kanthammal 33 F N N N N N N N N 3 N N N N N N 53 S 
87 Selvi 25 F N N N N N N N N 3 N N N N N N 58 L 
88 Devagi 17 F N y y N N y N N 4 y y y y y y 28 D 
89 Vasantha 48 F N N N N N N N N 2 N N N N N N 59 S 
90 Rajeswari 42 F N N N N N N N N 3 N N N N N N 39 S 
91 Kavitha 47 F y y y N N y y N 3 y y y y y y 43 S 
92 Seethammal 53 F N y N N N y N N 3 N y N N N N 28 H 
93 Vijaya 48 F N y N N N N N N 2 N N N N N N 56 L 
94 Fathima 56 F N N N N N y N N 3 N N N N N N 39 H 
95 Alicia 66 F y y y N N y N N 3 N y y N N y 36 H 
96 Mariammal 27 F N N N N N N N N 3 N y N N N N 42 S 
97 Velvizhi 33 F y N N N N y N N 3 N y N N N N 29 H 
98 Mary 35 F N y N N N N N N 3 N y N N N N 48 S 
99 Umarani 27 F N N N N N N y N 4 y y y y y y 50 H 
100 Raniammal 58 F N y N N N N N N 1 N N N N N N 58 S 
101 Sivakumar 69 M N N N N N N N N N N N N N N N N N 
102 Devendran 66 M N N N N N N N N N N N N N N N N N 
103 Chandran 66 M N N N N N N N N N N N N N N N N N 
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104 Vijayan 63 M N N N N N N N N N N N N N N N N N 
105 Baskar 65 M N N N N N N N N N N N N N N N N N 
106 Diwakar 60 M N N N N N N N N N N N N N N N N N 
107 Nagaraj 50 M N N N N N N N N N N N N N N N N N 
108 Kuppan 54 M N N N N N N N N N N N N N N N N N 
109 Chinnathambi 53 M N N N N N N N N N N N N N N N N N 
110 Ravanaiah 57 M N N N N N N N N N N N N N N N N N 
111 Chellapan 58 M N N N N N N N N N N N N N N N N N 
112 Pitchaiyah 59 M N N N N N N N N N N N N N N N N N 
113 Velan 52 M N N N N N N N N N N N N N N N N N 
114 Narayanan 28 M N N N N N N N N N N N N N N N N N 
115 Thangaraj 33 M N N N N N N N N N N N N N N N N N 
116 Chelladurai 34 M N N N N N N N N N N N N N N N N N 
117 Ashokan 40 M N N N N N N N N N N N N N N N N N 
118 Ponnusamy 41 M N N N N N N N N N N N N N N N N N 
119 Pitchandi 45 M N N N N N N N N N N N N N N N N N 
120 Zaheer 43 M N N N N N N N N N N N N N N N N N 
121 Aruldasan 47 M N N N N N N N N N N N N N N N N N 
122 Kumaravel 46 M N N N N N N N N N N N N N N N N N 
123 Durairaj 43 M N N N N N N N N N N N N N N N N N 
124 Gokulan 44 M N N N N N N N N N N N N N N N N N 
125 Hariharan 49 M N N N N N N N N N N N N N N N N N 
126 Poongavanan 48 M N N N N N N N N N N N N N N N N N 
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127 Shankar 49 M N N N N N N N N N N N N N N N N N 
128 Venkatiah 47 M N N N N N N N N N N N N N N N N N 
129 Samikannu 48 M N N N N N N N N N N N N N N N N N 
130 Francis 55 M N N N N N N N N N N N N N N N N N 
131 Ganapathy 77 M N N N N N N N N N N N N N N N N N 
132 Narasimhan 17 M N N N N N N N N N N N N N N N N N 
133 Damu 25 M N N N N N N N N N N N N N N N N N 
134 Ahmad 34 M N N N N N N N N N N N N N N N N N 
135 Nayagam 36 M N N N N N N N N N N N N N N N N N 
136 Jeyaraj 38 M N N N N N N N N N N N N N N N N N 
137 Deenadayalan 40 M N N N N N N N N N N N N N N N N N 
138 Sukumar 55 M N N N N N N N N N N N N N N N N N 
139 Kannaiah 57 M N N N N N N N N N N N N N N N N N 
140 Palaniappan 50 M N N N N N N N N N N N N N N N N N 
141 Appasamy 48 M N N N N N N N N N N N N N N N N N 
142 Manickam 49 M N N N N N N N N N N N N N N N N N 
143 Surendar 45 M N N N N N N N N N N N N N N N N N 
144 Sathyan 43 M N N N N N N N N N N N N N N N N N 
145 Umashankar 37 M N N N N N N N N N N N N N N N N N 
146 Vadivel 64 M N N N N N N N N N N N N N N N N N 
147 Ravindran 60 M N N N N N N N N N N N N N N N N N 
148 Balaji 59 M N N N N N N N N N N N N N N N N N 
149 Kuppaiah 51 M N N N N N N N N N N N N N N N N N 
119 
 
150 Dhanasekar 40 M N N N N N N N N N N N N N N N N N 
151 Raman 48 M N N N N N N N N N N N N N N N N N 
152 Kamalasekar 43 M N N N N N N N N N N N N N N N N N 
153 Prabhu 37 M N N N N N N N N N N N N N N N N N 
154 Raju 45 M N N N N N N N N N N N N N N N N N 
155 Napolean 52 M N N N N N N N N N N N N N N N N N 
156 Nirmal 66 M N N N N N N N N N N N N N N N N N 
157 Sundar 70 M N N N N N N N N N N N N N N N N N 
158 Shakthivel 65 M N N N N N N N N N N N N N N N N N 
159 Rajeev kumar 44 M N N N N N N N N N N N N N N N N N 
160 Samsuddin 40 M N N N N N N N N N N N N N N N N N 
161 Thanmbaiah 35 M N N N N N N N N N N N N N N N N N 
162 Jegadeesan 33 M N N N N N N N N N N N N N N N N N 
163 Balasubramani 47 M N N N N N N N N N N N N N N N N N 
164 Madhivanan 53 M N N N N N N N N N N N N N N N N N 
165 Madhavi 59 F N N N N N N N N N N N N N N N N N 
166 Shaheena 63 F N N N N N N N N N N N N N N N N N 
167 Gnanapriya 66 F N N N N N N N N N N N N N N N N N 
168 Malliga 62 F N N N N N N N N N N N N N N N N N 
169 Anthoniammal 60 F N N N N N N N N N N N N N N N N N 
170 Saraswathy 67 F N N N N N N N N N N N N N N N N N 
171 Masthan 58 F N N N N N N N N N N N N N N N N N 
172 Muthulaksmi 59 F N N N N N N N N N N N N N N N N N 
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173 Indradevi 53 F N N N N N N N N N N N N N N N N N 
174 Mangammal 54 F N N N N N N N N N N N N N N N N N 
175 Pavithra 56 F N N N N N N N N N N N N N N N N N 
176 Samithai 55 F N N N N N N N N N N N N N N N N N 
177 Gajalaksmi 53 F N N N N N N N N N N N N N N N N N 
178 Haripriya 46 F N N N N N N N N N N N N N N N N N 
179 Valli 48 F N N N N N N N N N N N N N N N N N 
180 Poongodi 44 F N N N N N N N N N N N N N N N N N 
181 Sadayammal 45 F N N N N N N N N N N N N N N N N N 
182 Pachayammal 43 F N N N N N N N N N N N N N N N N N 
183 Devi 32 F N N N N N N N N N N N N N N N N N 
184 Kasthuri 38 F N N N N N N N N N N N N N N N N N 
185 Thulasi 34 F N N N N N N N N N N N N N N N N N 
186 Shanmugapriya 33 F N N N N N N N N N N N N N N N N N 
187 Chithra 25 F N N N N N N N N N N N N N N N N N 
188 Janani 17 F N N N N N N N N N N N N N N N N N 
189 Sureka 48 F N N N N N N N N N N N N N N N N N 
190 Subammal 42 F N N N N N N N N N N N N N N N N N 
191 Thangammal 47 F N N N N N N N N N N N N N N N N N 
192 Saritha 53 F N N N N N N N N N N N N N N N N N 
193 Rita 48 F N N N N N N N N N N N N N N N N N 
194 Kannagi 56 F N N N N N N N N N N N N N N N N N 
195 Vimala 66 F N N N N N N N N N N N N N N N N N 
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196 Padmavathy 27 F N N N N N N N N N N N N N N N N N 
197 Pushpavathy 33 F N N N N N N N N N N N N N N N N N 
198 Latha 35 F N N N N N N N N N N N N N N N N N 
199 Usha 27 F N N N N N N N N N N N N N N N N N 
200 Esther 58 F N N N N N N N N N N N N N N N N N 
 
